American College of Cardiology

GIBBONS ET AL., MANAGEMENT OF PATIENTS WITH CHRONIC STABLE ANGINA UPDATE
http://www.acc.org/clinical/guidelines/stable/update_index.htm

ACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina

A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients With Chronic Stable Angina)

This is a Guideline Update of the 1999 Chronic Stable Angina Guidelines. To highlight the changes, deleted text is indicated by strikeout, and revised text is presented in brown. A clean version of the document, with changes fully incorporated, is available for download and print.

References

1. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996;28:1328-428. Reference deleted during update.

2. Braunwald E, Mark DB, Jones RH, et al. Unstable Angina: Diagnosis and Management. Clinical Practice Guideline Number 10. Rockville, (MD): Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, U.S. Department of Health and Human Services; 1994. AHCPR Publication No.: 94-0602. Reference deleted during update.

3. Elveback LR, Connolly DC, Melton LJ III. Coronary heart disease in residents of Rochester, Minnesota 7. Incidence, 1950 through 1982. Mayo Clin Proc 1986;61:896-900.

4. Kannel WB, Feinleib M. Natural history of angina pectoris in the Framingham study. Prognosis and survival. Am J Cardiol 1972;29:154-63.

5. The American Heart Association. 1999 Heart and Stroke Statistical Update. Dallas: American Heart Association, 1999.

6. Rouleau JL, Talajic M, Sussex B, et al. Myocardial infarction patients in the 1990s-their risk factors, stratification and survival in Canada: the Canadian Assessment of Myocardial Infarction (CAMI) Study. J Am Coll Cardiol 1996;27:1119-27.

7. Elveback LR, Connolly DC. Coronary heart disease in residents of Rochester, Minnesota, V. Prognosis of patients with coronary heart disease based on initial manifestation. Mayo Clin Proc 1985;60:305-11.

8. National Center for Health Statistics. Report of final mortality statistics, 1995. Hyattsville, Md: Public Health Service; 1997. Monthly vital statistics report. Vol 45, No. 11.

9. The American Heart Association. Biostatistical Fact Sheets. Dallas, TX: American Heart Association, 1997:1-29.

10. Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease: a multicenter randomized trial. Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. JAMA 1997;277:715-21.

11. Wennberg JE, Bubolz TA, Fisher ES, et al. The Dartmouth Atlas of Health Care in the United States. In: Cooper MM, ed. Chicago: American Hospital Publishing, 1996:123.

12. Ritchie JL, Bateman TM, Bonow RO, et al. Guidelines for clinical use of cardiac radionuclide imaging. Report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Radionuclide Imaging), developed in collaboration with the American Society of Nuclear Cardiology. J Am Coll Cardiol 1995;25:521-47.

13. Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA Guidelines for the Clinical Application of Echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. Circulation 1997;95:1686-744.

14. Gibbons RJ, Balady GJ, Beasley JW, Bricker JT, Duvernoy WFC, Froelicher VF, Mark DB, Marwick TH, McCallister BD, Thompson PD, Winters WL Jr, Yanowitz FG. ACC/AHA guidelines for exercise testing: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). J Am Coll Cardiol. 1997;30:260-315. Reference deleted during update.

15. Bonow RO, Carabello B, de Leon AC Jr, et al. ACC/AHA Guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Valvular Heart Disease). J Am Coll Cardiol 1998;32:1486-588.

16. Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA guidelines for ambulatory electrocardiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Ambulatory Electrocardiography). J Am Coll Cardiol 1999 (in review). Reference deleted during update.

17. Scanlon PJ, Faxon DP, Audet AM, et al. ACC/AHA guidelines for coronary angiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography). J Am Coll Cardiol 1999;33:1756-824.

18. Smith SC, Jr., Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous transluminal coronary angioplasty: a report of the ACC/AHA Task Force on Practice Guidelines (Committee on PTCA). J Am Coll Cardiol (in review). Reference deleted during update.

19. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA guidelines for coronary artery bypass graft surgery. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999;34:1262-347.

20. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89:1333-445. Reference deleted during update.

21. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46.

22. American College of Physicians. Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults. Part 1. Ann Intern Med 1996;124:515-7.

23. 27th Bethesda Conference. Matching the intensity of risk factor management with the hazard for coronary disease events. September 14-15, 1995. J Am Coll Cardiol 1996;27:957-1047.

24. Wenger NK, Froelicher ES, Smith LK, et al. Cardiac Rehabilitation. Clinical Practice Guideline No. 17. Rockville, Md: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute; 1995. AHCPR publication No. 96-0672.

25. Wexler L, Brundage B, Crouse J, et al. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association Writing Group. Circulation 1996;94:1175-92.

26. American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med 1992;117:1038-41. Reference deleted during update.

27. 20th Bethesda Conference. Insurability and employability of the patient with ischemic heart disease. October 3-4, 1988. J Am Coll Cardiol 1989;14:1004-44.

28. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation 1994;89: 1545-56.

29. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical Epidemiology, A Basic Science for Clinical Medicine. Boston:Little Brown, 1991:20.

30. Harris PJ, Behar VS, Conley MJ, et al. The prognostic significance of 50% coronary stenosis in medically treated patients with coronary artery disease. Circulation 1980;62:240-8.

31. Rutherford JD, Braunwald E. Chronic ischemic heart disease. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicines. 4th ed. Philadelphia: WB Saunders, 1992:1293-5.

32. Diamond GA. A clinically relevant classification of chest discomfort [letter]. J Am Coll Cardiol 1983;1:574-5.

33. Chatterjee K. Recognition and management of patients with stable angina pectoris. In: Goldman L, Braunwald E, eds. Primary Cardiology. Philadelphia: WB Saunders, 1998:234-56.

34. Levine HJ. Difficult problems in the diagnosis of chest pain. Am Heart J 1980;100:108-18.

35 Wise CM, Semble EL, Dalton CB. Musculoskeletal chest wall syndromes in patients with noncardiac chest pain: a study of 100 patients. Arch Phys Med Rehabil 1992;73:147-9.

36. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical Epidemiology, A Basic Science for Clinical Medicine Boston: Little Brown, 1991:93-8.

37. Mark DB, Shaw L, Harrell FE, et al. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med 1991;325:849-53.

38. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. N Engl J Med 1979;300:1350-8.

39. Pryor DB, Harrell FE, Lee KL, Califf RM, Rosati RA. Estimating the likelihood of significant coronary artery disease. Am J Med 1983;75:771-80.

40. Sox HC, Hickam DH, Marton KI, et al. Using the patient’s history to estimate the probability of coronary artery disease: a comparison of primary care and referral practices [published erratum appears in Am J Med 1990;89:550]. Am J Med 1990;89:7-14.

41. Pryor DB, Shaw L, McCants CB, et al. Value of the history and physical in identifying patients at increased risk for coronary artery disease. Ann Intern Med 1993;118:81-90.

42. Chaitman BR, Bourassa MG, Davis K, et al. Angiographic prevalence of high-risk coronary artery disease in patient subsets (CASS). Circulation 1981;64:360-7.

43. Evans AT. Sensitivity and specificity of the history and physical examination for coronary artery disease [letter; comment]. Ann Intern Med 1994;120:344-5.

44. Laskey WK. Assessment of cardiovascular risk: a return to basics [editorial]. Ann Intern Med 1993;118:149-50.

45. Diamond GA, Staniloff HM, Forrester JS, Pollock BH, Swan HJ. Computer-assisted diagnosis in the noninvasive evaluation of patients with suspected coronary disease. J Am Coll Cardiol 1983;1:444-55.

46. Campeau L. Grading of angina pectoris [letter]. Circulation 1976;54:522-3.

47. Knochel JP, Beisel WR, Herndon EG, Gerard ES, Barry KG. The renal, cardiovascular, hematologic and serum electrolyte abnormalities of heatstroke. Am J Med 1961;30:299-309.

48. Hollander JE. The management of cocaine-associated myocardial ischemia. N Engl J Med 1995;333:1267-72.

49 Connolly DC, Elveback LR, Oxman HA. Coronary heart disease in residents of Rochester, Minnesota, IV. Prognostic value of the resting electrocardiogram at the time of initial diagnosis of angina pectoris. Mayo Clin Proc 1984;59:247-50.

50. Levy D, Salomon M, D’Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994;90:1786-93.

51. Fisch C. Electrocardiography and vectorcardiography. In: Braunwald E, ed. Heart Disease. A Textbook of Cardiovascular Medicine. 4th ed. Philadelphia: WB Saunders, 1992:145.

52. Margolis JR, Chen JT, Kong Y, Peter RH, Behar VS, Kisslo JA. The diagnostic and prognostic significance of coronary artery calcification: a report of 800 cases. Radiology 1980;137:609-16.

53. Mautner SL, Mautner GC, Froehlich J, et al. Coronary artery disease: prediction with in vitro electron beam CT. Radiology 1994;192:625-30.

54. Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area: a histopathologic correlative study. Circulation 1995;92:2157-62.

55. Janowitz WR, Agatston AS, Viamonte M Jr. Comparison of serial quantitative evaluation of calcified coronary artery plaque by ultrafast computed tomography in persons with and without obstructive coronary artery disease. Am J Cardiol 1991;68:1-6.

56. Devries S, Wolfkiel C, Shah V, Chomka E, Rich S. Reproducibility of the measurement of coronary calcium with ultrafast computed tomography. Am J Cardiol 1995;75:973-5.

57. Detrano R, Wang S, Tang W, Brundage B, Wong N. Thick slice electron beam tomographic scanning allows reproducible and accurate assessments of coronary calcific deposits. Circulation 1995;92(suppl I):I-650.

58. Washington RL, Bricker JT, Alpert BS, et al. Guidelines for exercise testing in the pediatric age group. From the Committee on Atherosclerosis and Hypertension in Children, Council on Cardiovascular Disease in the Young, the American Heart Association. Circulation 1994;90:2166-79.

59. Fletcher GF, Balady G, Froelicher VF, Hartley LH, Haskell WL, Pollock ML. Exercise standards: a statement for healthcare professionals from the American Heart Association. Circulation 1995;91:580-615.

60. Pina IL, Balady GJ, Hanson P, Labovitz AJ, Madonna DW, Myers J. Guidelines for clinical exercise testing laboratories. A statement for healthcare professionals from the Committee on Exercise and Cardiac Rehabilitation, American Heart Association. Circulation 1995;91:912-21.

61. Stuart RJ, Ellestad MH. National survey of exercise stress testing facilities. Chest 1980;77:94-7.

62. Lewis WR, Amsterdam EA. Utility and safety of immediate exercise testing of low-risk patients admitted to the hospital for suspected acute myocardial infarction. Am J Cardiol 1994;74:987-90.

63. Gomez MA, Anderson JL, Karagounis LA, Muhlestein JB, Mooers FB. An emergency department-based protocol for rapidly ruling out myocardial ischemia reduces hospital time and expense: results of a randomized study (ROMIO). J Am Coll Cardiol 1996;28:25-33.

64. Polanczyk CA, Johnson PA, Hartley LH, Walls RM, Shaykevich S, Lee TH. Clinical correlates and prognostic significance of early negative exercise tolerance test in patients with acute chest pain seen in the hospital emergency department. Am J Cardiol 1998;81:288-92.

65. Brown KA, O’Meara J, Chambers CE, Plante DA. Ability of dipyridamole-thallium-201 imaging one to four days after acute myocardial infarction to predict in-hospital and late recurrent myocardial ischemic events. Am J Cardiol 1990;65:160-7.

66. Mahmarian JJ, Mahmarian AC, Marks GF, Pratt CM, Verani MS. Role of adenosine thallium-201 tomography for defining long-term risk in patients after acute myocardial infarction. J Am Coll Cardiol 1995;25:1333-40.

67. Dakik HA, Mahmarian JJ, Kimball KT, Koutelou MG, Medrano R, Verani MS. Prognostic value of exercise 201Tl tomography in patients treated with thrombolytic therapy during acute myocardial infarction. Circulation 1996;94:2735-42.

68. Heller GV, Brown KA, Landin RJ, Haber SB. Safety of early intravenous dipyridamole technetium 99m sestamibi SPECT myocardial perfusion imaging after uncomplicated first myocardial infarction: Early Post MI IV Dipyridamole Study (EPIDS). Am Heart J 1997;134:105-11.

69. Myers J, Froelicher VF. Optimizing the exercise test for pharmacological investigations. Circulation 1990;82:1839-46.

70. Schlant RC, Friesinger GC, Leonard JJ. Clinical competence in exercise testing. A statement for physicians from the ACP/ACC/AHA Task Force on Clinical Privileges in Cardiology. J Am Coll Cardiol 1990;16:1061-5.

71. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377-81.

72. Guidelines and indications for coronary artery bypass graft surgery. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol 1991;17:543-89.

73. Morise AP, Diamond GA. Comparison of the sensitivity and specificity of exercise electrocardiography in biased and unbiased populations of men and women. Am Heart J 1995;130:741-7.

74. DelCampo J, Do D, Umann T, McGowan V, Froning J, Froelicher VF. Comparison of computerized and standard visual criteria of exercise ECG for diagnosis of coronary artery disease. Ann Non-Invasive Electrocardiography [RTF annotation: Please verify journal title in reference 74.]1996;1:430-42.

75. Froelicher VF, Lehmann KG, Thomas R, et al. The electrocardiographic exercise test in a population with reduced workup bias: diagnostic performance, computerized interpretation, and multivariable prediction. Veterans Affairs Cooperative Study in Health Services #016 (QUEXTA) Study Group. Quantitative Exercise Testing and Angiography. Ann Intern Med 1998;128:965-74.

76. Ellestad MH, Savitz S, Bergdall D, Teske J. The false positive stress test. Multivariate analysis of 215 subjects with hemodynamic, angiographic and clinical data. Am J Cardiol 1977;40:681-5.

77. Yamada H, Do D, Morise A, Atwood JE, Froelicher VF. Review of studies using multivariable analysis of clinical and exercise test data to predict angiographic coronary artery disease. Prog Cardiovasc Dis 1997;39:457-81.

78. Lee KL, Pryor DB, Harrell FE, et al. Predicting outcome in coronary disease: statistical models versus expert clinicians. Am J Med 1986;80:553-60.

79. Detrano R, Bobbio M, Olson H, et al. Computer probability estimates of angiographic coronary artery disease: transportability and comparison with cardiologists’ estimates. Comput Biomed Res 1992;25:468-85.

80. Pauker SG, Kassirer JP. The threshold approach to clinical decision making. N Engl J Med 1980;302:1109-17.

81. Diamond GA, Forrester JS, Hirsch M, et al. Application of conditional probability analysis to the clinical diagnosis of coronary artery disease. J Clin Invest 1980;65:1210-21.

82. Goldman L, Cook EF, Mitchell N, et al. Incremental value of the exercise test for diagnosing the presence or absence of coronary artery disease. Circulation 1982;66:945-53.

83. Melin JA, Wijns W, Vanbutsele RJ, et al. Alternative diagnostic strategies for coronary artery disease in women: demonstration of the usefulness and efficiency of probability analysis. Circulation 1985;71:535-42.

84. Sketch MH, Mooss AN, Butler ML, Nair CK, Mohiuddin SM. Digoxin-induced positive exercise tests: their clinical and prognostic significance. Am J Cardiol 1981;48:655-9.

85. Le Winter MM, Crawford MH, O’Rourke RA, Karliner JS. The effects of oral propranolol, digoxin and combination therapy on the resting and exercise electrocardiogram. Am Heart J 1977;93:202-9.

86. Egstrup K. Transient myocardial ischemia after abrupt withdrawal of antianginal therapy in chronic stable angina. Am J Cardiol 1988;61:1219-22.

87. Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA 1990;263: 1653-7.

88. Cantwell JD, Murray PM, Thomas RJ. Current management of severe exercise-related cardiac events. Chest 1988;93:1264-9.

89. Anastasiou-Nana MI, Anderson JL, Stewart JR, et al. Occurrence of exercise-induced and spontaneous wide complex tachycardia during therapy with flecainide for complex ventricular arrhythmias: a probable proarrhythmic effect. Am Heart J 1987;113:1071-7.

90. Whinnery JE, Froelicher VF, Stuart AJ. The electrocardiographic response to maximal treadmill exercise in asymptomatic men with left bundle branch block. Am Heart J 1977;94:316-24.

91. Whinnery JE, Froelicher VF, Longo MR, Triebwasser JH. The electrocardiographic response to maximal treadmill exercise of asymptomatic men with right bundle branch block. Chest 1977;71:335-40.

92. Blackburn H. Canadian Colloquium on Computer-Assisted Interpretation of Electrocardiograms, VI. Importance of the electrocardiogram in populations outside the hospital. Can Med Assoc J 1973;108:1262-5.

93. Cullen K, Stenhouse NS, Wearne KL, Cumpston GN. Electrocardiograms and 13 year cardiovascular mortality in Busselton study. Br Heart J 1982;47:209-12.

94. Aronow WS. Correlation of ischemic ST-segment depression on the resting electrocardiogram with new cardiac events in 1,106 patients over 62 years of age. Am J Cardiol 1989;64:232-3.

95. Califf RM, Mark DB, Harrell FE, et al. Importance of clinical measures of ischemia in the prognosis of patients with documented coronary artery disease. J Am Coll Cardiol 1988;11:20-6.

96. Harris PJ, Harrell FE, Lee KL, Behar VS, Rosati RA. Survival in medically treated coronary artery disease. Circulation 1979;60:1259-69.

97. Miranda CP, Lehmann KG, Froelicher VF. Correlation between resting ST segment depression, exercise testing, coronary angiography, and long-term prognosis. Am Heart J 1991;122:1617-28.

98. Kansal S, Roitman D, Sheffield LT. Stress testing with ST-segment depression at rest. An angiographic correlation. Circulation 1976;54:636-9.

99. Harris FJ, DeMaria AN, Lee G, Miller RR, Amsterdam EA, Mason DT. Value and limitations of exercise testing in detecting coronary disease with normal and abnormal resting electrocardiograms. Adv Cardiol 1978:11-5.

100. Miranda CP, Liu J, Kadar A, et al. Usefulness of exercise-induced ST-segment depression in the inferior leads during exercise testing as a marker for coronary artery disease. Am J Cardiol 1992; 69:303-7.

101. Rijneke RD, Ascoop CA, Talmon JL. Clinical significance of upsloping ST segments in exercise electrocardiography. Circulation 1980;61:671-8.

102. Stuart RJ, Ellestad MH. Upsloping S-T segments in exercise stress testing. Six year follow-up study of 438 patients and correlation with 248 angiograms. Am J Cardiol 1976;37:19-22.

103. Sapin PM, Koch G, Blauwet MB, McCarthy JJ, Hinds SW, Gettes LS. Identification of false positive exercise tests with use of electrocardiographic criteria: a possible role for atrial repolarization waves. J Am Coll Cardiol 1991;18:127-35.

104. Sapin PM, Blauwet MB, Koch GG, Gettes LS. Exaggerated atrial repolarization waves as a predictor of false positive exercise tests in an unselected population. J Electrocardiol 1995;28:313-21.

105. Manvi KN, Ellestad MH. Elevated ST segments with exercise in ventricular aneurysm. J Electrocardiol 1972;5:317-23.

106. Haines DE, Beller GA,Watson DD, Kaiser DL, Sayre SL, Gibson RS. Exercise-induced ST segment elevation 2 weeks after uncomplicated myocardial infarction: contributing factors and prognostic significance. J Am Coll Cardiol 1987;9:996-1003.

107. Margonato A, Ballarotto C, Bonetti F, et al. Assessment of residual tissue viability by exercise testing in recent myocardial infarction: comparison of the electrocardiogram and myocardial perfusion scintigraphy. J Am Coll Cardiol 1992;19:948-52.

108. Margonato A, Chierchia SL, Xuereb RG, et al. Specificity and sensitivity of exercise-induced ST segment elevation for detection of residual viability: comparison with fluorodeoxyglucose and positron emission tomography. J Am Coll Cardiol 1995;25:1032-8.

109. Lombardo A, Loperfido F, Pennestri F, et al. Significance of transient ST-T segment changes during dobutamine testing in Q wave myocardial infarction. J Am Coll Cardiol 1996;27:599-605.

110. Kentala E, Luurila O. Response of R wave amplitude to postural changes and to exercise. A study of healthy subjects and patients surviving acute myocardial infarction. Ann Clin Res 1975;7:258-63.

111. Bonoris PE, Greenberg PS, Christison GW, Castellanet MJ, Ellestad MH. Evaluation of R wave amplitude changes versus STsegment depression in stress testing. Circulation 1978;57:904-10.

112. De Feyter PJ, Jong de JP, Roos JP, van Eenige MJ, de Jong JP. Diagnostic incapacity of exercise-induced QRS wave amplitude changes to detect coronary artery disease and left ventricular dysfunction. Eur Heart J 1982;3:9-16.

113. Elamin MS, Boyle R, Kardash MM, et al. Accurate detection of coronary heart disease by new exercise test. Br Heart J 1982;48:311-20.

114. Okin PM, Kligfield P. Computer-based implementation of the STsegment/heart rate slope. Am J Cardiol 1989;64:926-30.

115. Detrano R, Salcedo E, Passalacqua M, Friis R. Exercise electrocardiographic variables: a critical appraisal. J Am Coll Cardiol 1986;8:836-47.

116. Kligfield P, Ameisen O, Okin PM. Heart rate adjustment of ST segment depression for improved detection of coronary artery disease. Circulation 1989;79:245-55.

117. Lachterman B, Lehmann KG, Detrano R, Neutel J, Froelicher VF. Comparison of ST segment/heart rate index to standard ST criteria for analysis of exercise electrocardiogram. Circulation 1990;82:44-50.

118. Gianrossi R, Detrano R, Mulvihill D, et al. Exercise-induced ST depression in the diagnosis of coronary artery disease. A metaanalysis. Circulation 1989;80:87-98.

119. Pryor DB. The academic life cycle of a noninvasive test [editorial]. Circulation 1990;82:302-4.

120. Milliken JA, Abdollah H, Burggraf GW. False-positive treadmill exercise tests due to computer signal averaging. Am J Cardiol 1990;65:946-8.

121. Kennedy JW, Killip T, Fisher LD, Alderman EL, Gillespie MJ, Mock MD. The clinical spectrum of coronary artery disease and its surgical and medical management, 1974-1979. The Coronary Artery Surgery Study. Circulation 1982;66:III-16-23.

122. Hlatky MA, Pryor DB, Harrell FE, Califf RM, Mark DB, Rosati RA. Factors affecting sensitivity and specificity of exercise electrocardiography. Multivariable analysis. Am J Med 1984;77:64-71.

123. Linhart JW, Laws JG, Satinsky JD. Maximum treadmill exercise electrocardiography in female patients. Circulation 1974;50:1173-8.

124. Sketch MH, Mohiuddin SM, Lynch JD, Zencka AE, Runco V. Significant sex differences in the correlation of electrocardiographic exercise testing and coronary arteriograms. Am J Cardiol 1975;36:169-73.

125. Barolsky SM, Gilbert CA, Faruqui A, Nutter DO, Schlant RC. Differences in electrocardiographic response to exercise of women and men: a non-Bayesian factor. Circulation 1979;60:1021-7.

126. Ilsley C, Canepa-Anson R, Westgate C, Webb S, Rickards A, Poole-Wilson P. Influence of R wave analysis upon diagnostic accuracy of exercise testing in women. Br Heart J 1982;48:161-8.

127. Hung J, Chaitman BR, Lam J, et al. Noninvasive diagnostic test choices for the evaluation of coronary artery disease in women: a multivariate comparison of cardiac fluoroscopy, exercise electrocardiography and exercise thallium myocardial perfusion scintigraphy. J Am Coll Cardiol 1984;4:8-16.

128. Chae SC, Heo J, Iskandrian AS, Wasserleben V, Cave V. Identification of extensive coronary artery disease in women by exercise single-photon emission computed tomographic (SPECT) thallium imaging. J Am Coll Cardiol 1993;21:1305-11.

129. Marwick TH, Anderson T, Williams MJ, et al. Exercise echocardiography is an accurate and cost-efficient technique for detection of coronary artery disease in women. J Am Coll Cardiol 1995;26:335-41.

130. Williams MJ, Marwick TH, O’Gorman D, Foale RA. Comparison of exercise echocardiography with an exercise score to diagnose coronary artery disease in women. Am J Cardiol 1994;74:435-8.

131. Robert AR, Melin JA, Detry JM. Logistic discriminant analysis improves diagnostic accuracy of exercise testing for coronary artery disease in women. Circulation 1991;83:1202-9.

132. Okin PM, Kligfield P. Gender-specific criteria and performance of the exercise electrocardiogram. Circulation 1995;92:1209-16.

133. Pratt CM, Francis MJ, Divine GW, Young JB. Exercise testing in women with chest pain. Are there additional exercise characteristics that predict true positive test results? Chest 1989;95:139-44.

134. Pryor DB, Shaw L, Harrell FE, et al. Estimating the likelihood of severe coronary artery disease. Am J Med 1991;90:553-62.

135. Hubbard BL, Gibbons RJ, Lapeyre AC, Zinsmeister AR, Clements IP. Identification of severe coronary artery disease using simple clinical parameters. Arch Intern Med 1992;152:309-12.

136. DeStefano F, Merritt RK,Anda RF, Casper ML, Eaker ED. Trends in nonfatal coronary heart disease in the United States, 1980 through 1989. Arch Intern Med 1993;153:2489-94.

137. Fleg JL, Gerstenblith G, Zonderman AB, et al. Prevalence and prognostic significance of exercise-induced silent myocardial ischemia detected by thallium scintigraphy and electrocardiography in asymptomatic volunteers. Circulation 1990;81:428-36.

138. Vasilomanolakis EC. Geriatric cardiology: when exercise stress testing is justified. Geriatrics 1985;40:47-50.

139. Martinez-Caro D, Alegria E, Lorente D, Azpilicueta J, Calabuig J, Ancin R. Diagnostic value of stress testing in the elderly. Eur Heart J 1984;5(Suppl E):63-7.

140. Kasser IS, Bruce RA. Comparative effects of aging and coronary heart disease on submaximal and maximal exercise. Circulation 1969;39:759-74.

141. O’Keefe JH Jr, Zinsmeister AR, Gibbons RJ. Value of normal electrocardiographic findings in predicting resting left ventricular function in patients with chest pain and suspected coronary artery disease. Am J Med 1989;86:658-62.

142. Christian TF, Miller TD, Chareonthaitawee P, Hodge DO, O’Connor MK, Gibbons RJ. Prevalence of normal resting left ventricular function with normal rest electrocardiograms. Am J Cardiol 1997;79:1295-8.

143. Heger JJ, Weyman AE, Wann LS, Rogers EW, Dillon JC, Feigenbaum H. Cross-sectional echocardiographic analysis of the extent of left ventricular asynergy in acute myocardial infarction. Circulation 1980;61:1113-8.

144. Jaarsma W, Visser CA, van Eenige MJ, Verheugt FW, Kupper AJ, Roos JP. Predictive value of two-dimensional echocardiographic and hemodynamic measurements on admission with acute myocardial infarction. J Am Soc Echocardiogr 1988;1:187-93.

145. Roger VL, Pellikka PA, Oh JK, Miller FA, Seward JB, Tajik AJ. Stress echocardiography. Part I. Exercise echocardiography: techniques, implementation, clinical applications, and correlations. Mayo Clin Proc 1995;70:5-15.

146. Aurigemma GP, Gaasch WH, Villegas B, Meyer TE. Noninvasive assessment of left ventricular mass, chamber volume, and contractile function. Curr Probl Cardiol 1995;20:361-440.

147. Horowitz RS, Morganroth J, Parrotto C, Chen CC, Soffer J, Pauletto FJ. Immediate diagnosis of acute myocardial infarction by two-dimensional echocardiography. Circulation 1982;65:323-9.

148. Gibson RS, Bishop HL, Stamm RB, Crampton RS, Beller GA, Martin RP. Value of early two dimensional echocardiography in patients with acute myocardial infarction. Am J Cardiol 1982; 49:1110-9.

149. Kerber RE, Abboud FM. Echocardiographic detection of regional myocardial infarction: an experimental study. Circulation 1973;47:997-1005.

150. Weiss JL, Bulkley BH, Hutchins GM, Mason SJ. Two-dimensional echocardiographic recognition of myocardial injury in man: comparison with postmortem studies. Circulation 1981;63:401-8.

151. Nixon JV, Narahara KA, Smitherman TC. Estimation of myocardial involvement in patients with acute myocardial infarction by two-dimensional echocardiography. Circulation 1980;62:1248-55.

152. Distante A, Picano E, Moscarelli E, Palombo C, Benassi A, L’Abbate A. Echocardiographic versus hemodynamic monitoring during attacks of variant angina pectoris. Am J Cardiol 1985;55:1319-22.

153. Shibata J, Takahashi H, Itaya M, et al. Cross-sectional echocardiographic visualization of the infarcted site in myocardial infarction: correlation with electrocardiographic and coronary angiographic findings. J Cardiogr 1982;12:885-94.

154. Tennant R,Wiggers CJ. The effect of coronary artery occlusion on myocardial contraction. Am J Physiol 1935;112:351-61.

155. Burns PN. Harmonic imaging with ultrasound contrast agents. Clin Radiol 1996;51(Suppl 1):50-5.

156. Christopher T. Finite amplitude distortion-based inhomogeneous pulse echo ultrasonic imaging. IEEE Trans Ultrasonics Ferroelectrics Frequency Control 1997;44:125-39.

157. Kaul S, Glasheen WP, Oliner JD, Kelly P, Gascho JA. Relation between anterograde blood flow through a coronary artery and the size of the perfusion bed it supplies: experimental and clinical implications. J Am Coll Cardiol 1991;17:1403-13.

158. Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996;93:1993-9.

159. Porter T, Li S, Kilzer K, Deligonul U. Correlation between quantitative angiographic lesion severity and myocardial contrast intensity during a continuous infusion of perfluorocarbon-containing microbubbles. J Am Soc Echocardiogr 1998;11:702-10.

160. Peels CH, Visser CA, Kupper AJ, Visser FC, Roos JP. Usefulness of two-dimensional echocardiography for immediate detection of myocardial ischemia in the emergency room. Am J Cardiol 1990;65:687-91.

161. Kaul S, Spotnitz WD, Glasheen WP, Touchstone DA. Mechanism of ischemic mitral regurgitation. An experimental evaluation. Circulation 1991;84:2167-80.

162. Kono T, Sabbah HN, Rosman H, et al. Mechanism of functional mitral regurgitation during acute myocardial ischemia. J Am Coll Cardiol 1992;19:1101-5.

163. Godley RW, Wann LS, Rogers EW, Feigenbaum H, Weyman AE. Incomplete mitral leaflet closure in patients with papillary muscle dysfunction. Circulation 1981;63:565-71.

164. Nishimura RA, Schaff HV, Shub C, Gersh BJ, Edwards WD, Tajik AJ. Papillary muscle rupture complicating acute myocardial infarction: analysis of 17 patients. Am J Cardiol 1983;51:373-7.

165. Leppo JA. Dipyridamole-thallium imaging: the lazy man’s stress test. J Nucl Med 1989;30:281-7.

166. Abreu A, Mahmarian JJ, Nishimura S, Boyce TM, Verani MS. Tolerance and safety of pharmacologic coronary vasodilation with adenosine in association with thallium-201 scintigraphy in patients with suspected coronary artery disease. J Am Coll Cardiol 1991;18:730-5.

167. Verani MS. Adenosine thallium 201 myocardial perfusion scintigraphy. Am Heart J 1991;122:269-78.

168. Mason JR, Palac RT, Freeman ML, et al. Thallium scintigraphy during dobutamine infusion: nonexercise-dependent screening test for coronary disease. Am Heart J 1984;107:481-5.

169. Pennell DJ, Underwood SR, Swanton RH, Walker JM, Ell PJ. Dobutamine thallium myocardial perfusion tomography. J Am Coll Cardiol 1991;18:1471-9.

170. Marwick T, Willemart B, D’Hondt AM, et al. Selection of the optimal nonexercise stress for the evaluation of ischemic regional myocardial dysfunction and malperfusion. Comparison of dobutamine and adenosine using echocardiography and 99mTc-MIBI single photon emission computed tomography. Circulation 1993;87:345-54.

171. Hays JT, Mahmarian JJ, Cochran AJ, Verani MS. Dobutamine thallium-201 tomography for evaluating patients with suspected coronary artery disease unable to undergo exercise or vasodilator pharmacologic stress testing. J Am Coll Cardiol 1993;21:1583-90.

172. Mertes H, Sawada SG, Ryan T, et al. Symptoms, adverse effects, and complications associated with dobutamine stress echocardiography: experience in 1,118 patients. Circulation 1993;88:15-9.

173. Hiro J, Hiro T, Reid CL, Ebrahimi R, Matsuzaki M, Gardin JM. Safety and results of dobutamine stress echocardiography in women versus men and in patients older and younger than 75 years of age. Am J Cardiol 1997;80:1014-20.

174. Rozanski A, Diamond GA, Berman D, Forrester JS, Morris D, Swan HJC. The declining specificity of exercise radionuclide ventriculography. N Engl J Med 1983;309:518-22.

175. Douglas PS. Is noninvasive testing for coronary artery disease accurate? Circulation 1997;95:299-302.

176. Kaul S. Technical, economic, interpretative, and outcomes issues regarding utilization of cardiac imaging techniques in patients with known or suspected coronary artery disease. Am J Cardiol 1995;75:18D-24D.

177. Diamond GA. Reverend Bayes’ silent majority: an alternative factor affecting sensitivity and specificity of exercise electrocardiography. Am J Cardiol 1986;57:1175-80.

178. Schwartz RS, Jackson WG, Cello PV, Richardson LA, Hickman JR. Accuracy of exercise 201-Tl myocardial scintigraphy in asymptomatic young men. Circulation 1993;87:165-72.

179. Roger VL, Pelikka PA, Bell MR, Chow CWH, Bailey KR, Seward JB. Sex and test verification bias: impact on the diagnostic value of exercise echocardiography. Circulation 1997;95:405-10.

180. Kiat H, Berman DS, Maddahi J. Comparison of planar and tomographic exercise thallium-201 imaging methods for the evaluation of coronary artery disease. J Am Coll Cardiol 1989;13:613-6.

181. Iskandrian AS, Heo J, Kong B, Lyons E, Marsch S. Use of technetium-99m isonitrile (RP-30A) in assessing left ventricular perfusion and function at rest and during exercise in coronary artery disease, and comparison with coronary arteriography and exercise thallium-201 SPECT imaging. Am J Cardiol 1989;64:270-5.

182. Taillefer R, Laflamme L, Dupras G, Picard M, Phaneuf DC, Leveille J. Myocardial perfusion imaging with 99mTc-methoxyisobutyl-isonitrile (MIBI): comparison of short and long time intervals between rest and stress injections. Preliminary results. Eur J Nucl Med 1988;13:515-22.

183. Maddahi J, Kiat H, Van Train KF, et al. Myocardial perfusion imaging with technetium-99m sestamibi SPECT in the evaluation of coronary artery disease. Am J Cardiol 1990;66:55E-62E.

184. Kahn JK, McGhie I, Akers MS, et al. Quantitative rotational tomography with 201Tl and 99mTc 2-methoxy-isobutyl-isonitrile. A direct comparison in normal individuals and patients with coronary artery disease. Circulation 1989;79:1282-93.

185. Wackers FJ, Berman DS, Maddahi J, et al. Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 1989;30:301-11.

186. Maisey MN, Mistry R, Sowton E. Planar imaging techniques used with technetium-99m sestamibi to evaluate chronic myocardial ischemia. Am J Cardiol 1990;66:47E-54E.

187. Maddahi J, Kiat H, Friedman JD, Berman DS, Van Train KK, Garcia EV. Technetium-99m-sestamibi myocardial perfusion imaging for evaluation of coronary artery disease. In: Zaret BL, Beller GA, eds. Nuclear Cardiology: State of the Art and Future Directions. St. Louis: Mosby, 1993:191-200.

188. Verani MS. Thallium-201 and technetium-99m perfusion agents: where we are in 1992. In: Zaret BL, Beller GA, eds. Nuclear Cardiology: State of the Art and Future Directions. St. Louis:Mosby, 1993:216-24.

189. Sridhara BS, Braat S, Rigo P, Itti R, Cload P, Lahiri A. Comparison of myocardial perfusion imaging with technetium-99m tetrofosmin versus thallium-201 in coronary artery disease. Am J Cardiol 1993;72:1015-9.

190. Zaret BL, Rigo P, Wackers FJ, et al. Myocardial perfusion imaging with 99mTc tetrofosmin. Comparison to 201Tl imaging and coronary angiography in a phase III multicenter trial. Circulation 1995;91:313-9.

191. Verani MS, Marcus ML, Razzak MA, Ehrhardt JC. Sensitivity and specificity of thallium-201 perfusion scintigrams under exercise in the diagnosis of coronary artery disease. J Nucl Med 1978;19:773-82.

192. Okada RD, Boucher CA, Strauss HW, Pohost GM. Exercise radionuclide imaging approaches to coronary artery disease. Am J Cardiol 1980;46:1188-204.

193. Gibson RS, Beller GA. Should exercise electrocardiographic testing be replaced by radioscope methods? In: Rahimtoola SH, Brest AN, eds. Controversies in Coronary Artery Disease. Philadelphia: FA Davis, 1983:1-31.

194. Detrano R, Janosi A, Lyons KP, Marcondes G, Abbassi N, Froelicher VF. Factors affecting sensitivity and specificity of a diagnostic test: the exercise thallium scintigram. Am J Med 1988;84:699-710.

195. Watson DD, Campbell NP, Read EK, Gibson RS, Teates CD, Beller GA. Spatial and temporal quantitation of plane thallium myocardial images. J Nucl Med 1981;22:577-84.

196. Burow RD, Pond M, Schafer AW, Becker L. Circumferential profiles: a new method for computer analysis of thallium-201 myocardial perfusion images. J Nucl Med 1979;20:771-7.

197. Garcia E, Maddahi J, Berman D, Waxman A. Space/time quantitation of thallium-201 myocardial scintigraphy. J Nucl Med 1981;22:309-17.

198. Wackers FJ, Fetterman RC, Mattera JA, Clements JP. Quantitative planar thallium-201 stress scintigraphy: a critical evaluation of the method. Semin Nucl Med 1985;15:46-66.

199. Kaul S, Boucher CA, Newell JB, et al. Determination of the quantitative thallium imaging variables that optimize detection of coronary artery disease. J Am Coll Cardiol 1986;7:527-37.

200. Zaret BL, Wackers FJT, Soufer R. Nuclear cardiology. In: Braunwald E, ed. Heart Disease. Philadelphia: Saunders, 1992:276-311.

201. Maddahi J, Garcia EV, Berman DS, Waxman A, Swan HJ, Forrester J. Improved noninvasive assessment of coronary artery disease by quantitative analysis of regional stress myocardial distribution and washout of thallium-201. Circulation 1981;64:924-35.

202. Gerson MC, Thomas SR,Van Heertum RL. Tomographic myocardial perfusion imaging. In: Gerson MC, ed. Cardiac Nuclear Medicine. New York: McGraw-Hill, 1991:25-52.

203. White CW,Wright CB, Doty DB, et al. Does visual interpretation of the coronary arteriogram predict the physiologic importance of a coronary stenosis? N Engl J Med 1984;310:819-24.

204. Fintel DJ, Links JM, Brinker JA, Frank TL, Parker M, Becker LC. Improved diagnostic performance of exercise thallium-201 single photon emission computed tomography over planar imaging in the diagnosis of coronary artery disease: a receiver operating characteristic analysis. J Am Coll Cardiol 1989;13:600-12.

205. Nohara R, Kambara H, Suzuki Y, et al. Stress scintigraphy using single-photon emission computed tomography in the evaluation of coronary artery disease. Am J Cardiol 1984;53:1250-4.

206. Mahmarian JJ, Verani MS. Exercise thallium-201 perfusion scintigraphy in the assessment of coronary artery disease. Am J Cardiol 1991;67:2D-11D.

207. Gould KL. Noninvasive assessment of coronary stenoses by myocardial perfusion imaging during pharmacologic coronary vasodilatation, I. Physiologic basis and experimental validation. Am J Cardiol 1978;41:267-78.

208. Gould KL, Westcott RJ, Albro PC, Hamilton GW. Noninvasive assessment of coronary stenoses by myocardial imaging during pharmacologic coronary vasodilatation, II. Clinical methodology and feasibility. Am J Cardiol 1978;41:279-87.

209. Albro PC, Gould KL, Westcott RJ, Hamilton GW, Ritchie JL, Williams DL. Noninvasive assessment of coronary stenoses by myocardial imaging during pharmacologic coronary vasodilatation, III. Clinical trial. Am J Cardiol 1978;42:751-60.

210. Nishimura S, Mahmarian JJ, Boyce TM, Verani MS. Quantitative thallium-201 single-photon emission computed tomography during maximal pharmacologic coronary vasodilation with adenosine for assessing coronary artery disease. J Am Coll Cardiol1991;18:736-45.

211. Verani MS, Mahmarian JJ, Hixson JB, Boyce TM, Staudacher RA. Diagnosis of coronary artery disease by controlled coronary vasodilation with adenosine and thallium-201 scintigraphy in patients unable to exercise. Circulation 1990;82:80-7.

212. Nguyen T, Heo J, Ogilby JD, Iskandrian AS. Single photon emission computed tomography with thallium-201 during adenosineinduced coronary hyperemia: correlation with coronary arteriography, exercise thallium imaging and two-dimensional echocardiography. J Am Coll Cardiol 1990;16:1375-83.

213. Coyne EP, Belvedere DA, Vande Streek PR, Weiland FL, Evans RB, Spaccavento LJ. Thallium-201 scintigraphy after intravenous infusion of adenosine compared with exercise thallium testing in the diagnosis of coronary artery disease. J Am Coll Cardiol 1991; 17:1289-94.

214. Gupta NC, Esterbrooks DJ, Hilleman DE, Mohiuddin SM. Comparison of adenosine and exercise thallium-201 single-photon emission computed tomography (SPECT) myocardial perfusion imaging. The GE SPECT Multicenter Adenosine Study Group. J Am Coll Cardiol 1992;19:248-57.

215. Ogilby JD, Iskandrian AS, Untereker WJ, Heo J, Nguyen TN, Mercuro J. Effect of intravenous adenosine infusion on myocardial perfusion and function: hemodynamic/angiographic and scintigraphic study. Circulation 1992;86:887-95.

216. Nishimura S, Mahmarian JJ, Boyce TM, Verani MS. Equivalence between adenosine and exercise thallium-201 myocardial tomography: a multicenter, prospective, crossover trial. J Am Coll Cardiol 1992;20:265-75.

217. Verani MS. Pharmacologic stress myocardial perfusion imaging. Curr Probl Cardiol 1993;18:481-525.

218. Borges-Neto S, Mahmarian JJ, Jain A, Roberts R, Verani MS. Quantitative thallium-201 single photon emission computed tomography after oral dipyridamole for assessing the presence, anatomic location and severity of coronary artery disease. J Am Coll Cardiol 1988;11:962-9.

219. Kettunen R, Huikuri HV, Heikkila J, Takkunen JT. Usefulness of technetium-99m-MIBI and thallium-201 in tomographic imaging combined with high-dose dipyridamole and handgrip exercise for detecting coronary artery disease. Am J Cardiol 1991;68:575-9.

220. Parodi O, Marcassa C, Casucci R, et al. Accuracy and safety of technetium-99m hexakis 2-methoxy-2-isobutyl isonitrile (Sestamibi) myocardial scintigraphy with high dose dipyridamole test in patients with effort angina pectoris: a multicenter study. Italian Group of Nuclear Cardiology. J Am Coll Cardiol 1991;18:1439-44.

221. Wu JC, Yun JJ, Heller EN, et al. Limitations of dobutamine for enhancing flow heterogeneity in the presence of single coronary stenosis: implications for technetium-99m-sestamibi imaging. J Nucl Med 1998;39:417-25.

222. Calnon DA, Glover DK, Beller GA, et al. Effects of dobutamine stress on myocardial blood flow, 99mTc sestamibi uptake, and systolic wall thickening in the presence of coronary artery stenoses: implications for dobutamine stress testing. Circulation 1997;96:2353-60.

223. Iftikhar I, Koutelou M, Mahmarian JJ, Verani MS. Simultaneous perfusion tomography and radionuclide angiography during dobutamine stress. J Nucl Med 1996;37:1306-10.

224. Beleslin BD, Ostojic M, Stepanovic J, et al. Stress echocardiography in the detection of myocardial ischemia. Head-to-head comparison of exercise, dobutamine, and dipyridamole tests. Circulation 1994;90:1168-76.

225. Dagianti A, Penco M, Agati L, Sciomer S, Rosanio S, Fedele F. Stress echocardiography: comparison of exercise, dipyridamole and dobutamine in detecting and predicting the extent of coronary artery disease [published erratum appears in J Am Coll Cardiol 1995;26:1114]. J Am Coll Cardiol 1995;26:18-25.

226. Iskandrian AS, Heo J, Kong B, Lyons E. Effect of exercise level on the ability of thallium-201 tomographic imaging in detecting coronary artery disease: analysis of 461 patients. J Am Coll Cardiol 1989;14:1477-86.

227. Steele P, Sklar J, Kirch D, Vogel R, Rhodes CA. Thallium-201 myocardial imaging during maximal and submaximal exercise: comparison of submaximal exercise with propranolol. Am Heart J 1983;106:1353-7.

228. Hockings B, Saltissi S, Croft DN, Webb-Peploe MM. Effect of beta adrenergic blockade on thallium-201 myocardial perfusion imaging. Br Heart J 1983;49:83-9.

229. Martin GJ, Henkin RE, Scanlon PJ. Beta blockers and the sensitivity of the thallium treadmill test. Chest 1987;92:486-7.

230. Zacca NM,Verani MS, Chahine RA, Miller RR. Effect of nifedipine on exercise-induced left ventricular dysfunction and myocardial hypoperfusion in stable angina. Am J Cardiol 1982;50:689-95.

231. Esquivel L, Pollock SG, Beller GA, Gibson RS,Watson DD, Kaul S. Effect of the degree of effort on the sensitivity of the exercise thallium-201 stress test in symptomatic coronary artery disease. Am J Cardiol 1989;63:160-5.

232. Braat SH, Brugada P, Bar FW, Gorgels AP,Wellens HJ. Thallium-201 exercise scintigraphy and left bundle branch block. Am J Cardiol 1985;55:224-6.

233. Hirzel HO, Senn M, Nuesch K, et al. Thallium-201 scintigraphy in complete left bundle branch block. Am J Cardiol 1984;53:764-9.

234. DePuey EG, Guertler-Krawczynska E, Robbins WL. Thallium-201 SPECT in coronary artery disease patients with left bundle branch block. J Nucl Med 1988;29:1479-85.

235. Burns RJ, Galligan L, Wright LM, Lawand S, Burke RJ, Gladstone PJ. Improved specificity of myocardial thallium-201 single-photon emission computed tomography in patients with left bundle branch block by dipyridamole. Am J Cardiol 1991;68:504-8.

236. Rockett JF, Wood WC, Moinuddin M, Loveless V, Parrish B. Intravenous dipyridamole thallium-201 SPECT imaging in patients with left bundle branch block. Clin Nucl Med 1990;15:401-7.

237. O’Keefe JH Jr, Bateman TM, Barnhart CS. Adenosine thallium-201 is superior to exercise thallium-201 for detecting coronary artery disease in patients with left bundle branch block. J Am Coll Cardiol 1993;21:1332-8.

238. Vaduganathan P, He ZX, Raghavan C, Mahmarian JJ, Verani MS. Detection of left anterior descending coronary artery stenosis in patients with left bundle branch block: exercise, adenosine or dobutamine imaging? J Am Coll Cardiol 1996;28:543-50.

239. Morais J, Soucy JP, Sestier F, Lamoureux F, Lamoureux J, Danais S. Dipyridamole testing compared to exercise stress for thallium-201 imaging in patients with left bundle branch block. Can J Cardiol 1990;6:5-8.

240. Jukema JW, van der Wall EE, van der Vis-Melsen MJ, Kruyswijk HH, Bruschke AV. Dipyridamole thallium-201 scintigraphy for improved detection of left anterior descending coronary artery stenosis in patients with left bundle branch block. Eur Heart J 1993;14:53-6.

241. Larcos G, Brown ML, Gibbons RJ. Role of dipyridamole thallium-201 imaging in left bundle branch block. Am J Cardiol 1991;68:1097-8.

242. Patel R, Bushnell DL,Wagner R, Stumbris R. Frequency of false-positive septal defects on adenosine/201Tl images in patients with left bundle branch block. Nucl Med Commun 1995;16:137-9.

243. Lebtahi NE, Stauffer JC, Delaloye AB. Left bundle branch block and coronary artery disease: accuracy of dipyridamole thallium-201 single-photon emission computed tomography in patients with exercise anteroseptal perfusion defects. J Nucl Cardiol 1997;4:266-73.

244. Mairesse GH, Marwick TH, Arnese M, et al. Improved identification of coronary artery disease in patients with left bundle branch block by use of dobutamine stress echocardiography and comparison with myocardial perfusion tomography. Am J Cardiol 1995;76:321-5.

245. Osbakken MD, Okada RD, Boucher CA, Strauss HW, Pohost GM. Comparison of exercise perfusion and ventricular function imaging: an analysis of factors affecting the diagnostic accuracy of each technique. J Am Coll Cardiol 1984;3:272-83.

246. DePuey EG, Rozanski A. Using gated technetium-99m-sestamibi SPECT to characterize fixed myocardial defects as infarct or artifact. J Nucl Med 1995;36:952-5.

247. Smanio PE, Watson DD, Segalla DL, Vinson EL, Smith WH, Beller GA. Value of gating of technetium-99m sestamibi singlephoton emission computed tomographic imaging. J Am Coll Cardiol 1997;30:1687-92.

248. Taillefer R, DePuey EG, Udelson JE, Beller GA, Latour Y, Reeves F. Comparative diagnostic accuracy of Tl-201 and Tc-99m sestamibi SPECT imaging (perfusion and ECG-gated SPECT) in detecting coronary artery disease in women. J Am Coll Cardiol 1997;29:69-77.

249. O’Keefe JH, Barnhart CS, Bateman TM. Comparison of stress echocardiography and stress myocardial perfusion scintigraphy for diagnosing coronary artery disease and assessing its severity. Am J Cardiol 1995;75:25D-34D.

250. Fleischmann KE, Hunink MG, Kuntz KM, Douglas PS. Exercise echocardiography or exercise SPECT imaging: a meta-analysis of diagnostic test performance. JAMA 1998;280:913-20.

251. Patterson RE, Eisner RL. Cost analysis of noninvasive testing. In: Marwick TH, ed. Cardiac Stress Testing and Imaging: A Clinician’s Guide. New York: Churchill Livingstone, 1996;5:113-24.

252. Leung DY, Dawson IG, Thomas JD, Marwick TH. Accuracy and cost-effectiveness of exercise echocardiography for detection of coronary artery disease in patients with mitral valve prolapse. Am Heart J 1997;134:1052-7.

253. Kim C, Kwok YS, Saha S, Redberg RF. Diagnosis of suspected coronary artery disease in women: a cost-effectiveness analysis. Am Heart J 1999;137:1019-27.

254. Porter TR, Li S, Kilzer K, Deligonul U. Effect of significant two-vessel versus one-vessel coronary artery stenosis on myocardial contrast defects observed with intermittent harmonic imaging after intravenous contrast injection during dobutamine stress echocardiography. J Am Coll Cardiol 1997;30:1399-406.

255. Porter TR, Kricsfeld A, Deligonul U, Xie F. Detection of regional perfusion abnormalities during adenosine stress echocardiography with intravenous perfluorocarbon-exposed sonicated dextrose albumin. Am Heart J 1996;132:41-7.

256. O’Connor MK, Caiati C, Christian TF, Gibbons RJ. Effects of scatter correction on the measurement of infarct size from SPECT cardiac phantom studies. J Nucl Med 1995;36:2080-6.

257. Germano G, Erel J, Lewin H, Kavanagh PB, Berman DS. Automatic quantitation of regional myocardial wall motion and thickening from gated technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. J Am Coll Cardiol 1997;30:1360-7.

258. Ficaro EP, Fessler JA, Shreve PD, Kritzman JN, Rose PA, Corbett JR. Simultaneous transmission/emission myocardial perfusion tomography. Diagnostic accuracy of attenuation-corrected 99mTc-sestamibi single-photon emission computed tomography. Circulation 1996;93:463-73.

259. Tamaki N, Yonekura Y, Mukai T, et al. Stress thallium-201 transaxial emission computed tomography: quantitative versus qualitative analysis for evaluation of coronary artery disease. J Am Coll Cardiol 1984;4:1213-21.

260. DePasquale EE, Nody AC, DePuey EG, et al. Quantitative rotational thallium-201 tomography for identifying and localizing coronary artery disease. Circulation 1988;77:316-27.

261. Maddahi J, Van Train K, Prigent F, et al. Quantitative single photon emission computed thallium-201 tomography for detection and localization of coronary artery disease: optimization and prospective validation of a new technique. J Am Coll Cardiol 1989;14:1689-99.

262. Van Train KF, Maddahi J, Berman DS, et al. Quantitative analysis of tomographic stress thallium-201 myocardial scintigrams: a multicenter trial. J Nucl Med 1990;31:1168-79.

263. Mahmarian JJ, Boyce TM, Goldberg RK, Cocanougher MK, Roberts R, Verani MS. Quantitative exercise thallium-201 single photon emission computed tomography for the enhanced diagnosis of ischemic heart disease. J Am Coll Cardiol 1990;15:318-29.

264. Quiñones MA, Verani MS, Haichin RM, Mahmarian JJ, Suarez J, Zoghbi WA. Exercise echocardiography versus 201Tl single-photon emission computed tomography in evaluation of coronary artery disease: analysis of 292 patients. Circulation 1992;85:1026-31.

265. Christian TF, Miller TD, Bailey KR, Gibbons RJ. Noninvasive identification of severe coronary artery disease using exercise tomographic thallium-201 imaging. Am J Cardiol 1992;70:14-20.

266. Solot G, Hermans J, Merlo P, et al. Correlation of 99mTc-sestamibi SPECT with coronary angiography in general hospital practice. Nucl Med Commun 1993;14:23-9.

267. Van Train KF, Garcia EV, Maddahi J, et al. Multicenter trial validation for quantitative analysis of same-day rest-stress technetium-99m-sestamibi myocardial tomograms. J Nucl Med 1994;35:609-18.

268. Rubello D, Zanco P, Candelpergher G, et al. Usefulness of 99mTc-MIBI stress myocardial SPECT bull’s-eye quantification in coronary artery disease. Q J Nucl Med 1995;39:111-5.

269. Iskandrian AE, Heo J, Nallamothu N. Detection of coronary artery disease in women with use of stress single-photon emission computed tomography myocardial perfusion imaging. J Nucl Cardiol 1997;4:329-35.

270. Palmas W, Friedman JD, Diamond GA, Silber H, Kiat H, Berman DS. Incremental value of simultaneous assessment of myocardial function and perfusion with technetium-99m sestamibi for prediction of extent of coronary artery disease. J Am Coll Cardiol 1995;25:1024-31.

271. Berman DS, Kiat H, Friedman JD, et al. Separate acquisition rest thallium-201/stress technetium-99m sestamibi dual-isotope myocardial perfusion single-photon emission computed tomography: a clinical validation study. J Am Coll Cardiol 1993;22:1455-64.

272. Kiat H,Van Train KF,Maddahi J, et al. Development and prospective application of quantitative 2-day stress-rest Tc-99m methoxy isobutyl isonitrile SPECT for the diagnosis of coronary artery disease. Am Heart J 1990;120:1255-66.

273. Van Train KF, Areeda J, Garcia EV, et al. Quantitative same-day rest-stress technetium-99m-sestamibi SPECT: definition and validation of stress normal limits and criteria for abnormality. J Nucl Med 1993;34:1494-502.

274. Fleming RM, Kirkeeide RL, Taegtmeyer H, Adyanthaya A, Cassidy DB, Goldstein RA. Comparison of technetium-99m teboroxime tomography with automated quantitative coronary arteriography and thallium-201 tomographic imaging. J Am Coll Cardiol 1991;17:1297-302.

275. Minoves M, Garcia A, Magrina J, Pavia J, Herranz R, Setoain J. Evaluation of myocardial perfusion defects by means of bull’s eye images. Clin Cardiol 1993;16:16-22.

276. Heiba SI, Hayat NJ, Salman HS, et al. Technetium-99m-MIBI myocardial SPECT: supine versus right lateral imaging and comparison with coronary arteriography. J Nucl Med 1997;38:1510-14.

277. Sylven C, Hagerman I, Ylen M, Nyquist O, Nowak J. Variance ECG detection of coronary artery disease-a comparison with exercise stress test and myocardial scintigraphy. Clin Cardiol 1994;17:132-40.

278. Hecht HS, DeBord L, Shaw R, et al. Supine bicycle stress echocardiography versus tomographic thallium-201 exercise imaging for the detection of coronary artery disease. J Am Soc Echocardiogr 1993;6:177-85.

279. Pozzoli MM, Fioretti PM, Salustri A, Reijs AE, Roelandt JR. Exercise echocardiography and technetium-99m MIBI singlephoton emission computed tomography in the detection of coronary artery disease. Am J Cardiol 1991;67:350-5.

280. Hoffmann R, Lethen H, Kleinhans E, Weiss M, Flachskampf FA, Hanrath P. Comparative evaluation of bicycle and dobutamine stress echocardiography with perfusion scintigraphy and bicycle electrocardiogram for identification of coronary artery disease. Am J Cardiol 1993;72:555-9.

281. Oguzhan A, Kisacik HL, Ozdemir K, et al. Comparison of exercise stress testing with dobutamine stress echocardiography and exercise technetium-99m isonitrile single photon emission computerized tomography for diagnosis of coronary artery disease. Jpn Heart J 1997;38:333-44.

282. Ho YL, Wu CC, Huang PJ, et al. Assessment of coronary artery disease in women by dobutamine stress echocardiography: comparison with stress thallium-201 single-photon emission computed tomography and exercise electrocardiography. Am Heart J 1998;135:655-62.

283. Ho YL, Wu CC, Huang PJ, et al. Dobutamine stress echocardiography compared with exercise thallium-201 single-photon emission computed tomography in detecting coronary artery diseaseeffect of exercise level on accuracy. Cardiology 1997;88:379-85.

284. Armstrong WF, O’Donnell J, Ryan T, Feigenbaum H. Effect of prior myocardial infarction and extent and location of coronary disease on accuracy of exercise echocardiography. J Am Coll Cardiol 1987;10:531-8.

285. Crouse LJ, Harbrecht JJ, Vacek JL, Rosamond TL, Kramer PH. Exercise echocardiography as a screening test for coronary artery disease and correlation with coronary arteriography. Am J Cardiol 1991;67:1213-8.

286. Marwick TH, Nemec JJ, Pashkow FJ, Stewart WJ, Salcedo EE. Accuracy and limitations of exercise echocardiography in a routine clinical setting. J Am Coll Cardiol 1992;19:74-81.

287. Ryan T, Segar DS, Sawada SG, et al. Detection of coronary artery disease with upright bicycle exercise echocardiography. J Am Soc Echocardiogr 1993;6:186-97.

288. Hecht HS, DeBord L, Shaw R, et al. Digital supine bicycle stress echocardiography: a new technique for evaluating coronary artery disease. J Am Coll Cardiol 1993;21:950-6.

289. Roger VL, Pellikka PA, Oh JK, Bailey KR, Tajik AJ. Identification of multivessel coronary artery disease by exercise echocardiography. J Am Coll Cardiol 1994;24:109-14.

290. Marwick TH, Torelli J, Harjai K, et al. Influence of left ventricular hypertrophy on detection of coronary artery disease using exercise echocardiography. J Am Coll Cardiol 1995;26:1180-6.

291. Luotolahti M, Saraste M, Hartiala J. Exercise echocardiography in the diagnosis of coronary artery disease. Ann Med 1996;28:73-7.

292. Tawa CB, Baker WB, Kleiman NS, Trakhtenbroit A, Desir R, Zoghbi WA. Comparison of adenosine echocardiography, with and without isometric handgrip, to exercise echocardiography in the detection of ischemia in patients with coronary artery disease. J Am Soc Echocardiogr 1996;9:33-43.

293. Bjornstad K, Aakhus S, Hatle L. Comparison of digital dipyridamole stress echocardiography and upright bicycle stress echocardiography for identification of coronary artery stenosis. Cardiology 1995;86:514-20.

294. Marangelli V, Iliceto S, Piccinni G, De Martino G, Sorgente L, Rizzon P. Detection of coronary artery disease by digital stress echocardiography: comparison of exercise, transesophageal atrial pacing and dipyridamole echocardiography. J Am Coll Cardiol 1994;24:117-24.

295. Salustri A, Pozzoli MM, Hermans W, et al. Relationship between exercise echocardiography and perfusion single-photon emission computed tomography in patients with single-vessel coronary artery disease. Am Heart J 1992;124:75-83.

296. Galanti G, Sciagra R, Comeglio M, et al. Diagnostic accuracy of peak exercise echocardiography in coronary artery disease: comparison with thallium-201 myocardial scintigraphy. Am Heart J 1991;122:1609-16.

297. Ryan T, Vasey CG, Presti CF, O’Donnell JA, Feigenbaum H, Armstrong WF. Exercise echocardiography: detection of coronary artery disease in patients with normal left ventricular wall motion at rest. J Am Coll Cardiol 1988;11:993-9.

298. Alam M, Hoglund C, Thorstrand C, Carlens P. Effects of exercise on the displacement of the atrioventricular plane in patients with coronary artery disease: a new echocardiographic method of detecting reversible myocardial ischaemia. Eur Heart J 1991;12:760-5.

299. Tian J, Zhang G, Wang X, Cui J, Xiao J. Exercise echocardiography: feasibility and value for detection of coronary artery disease. Chin Med J (Engl) 1996;105:381-4.

300. O’Keefe JH Jr, Bateman TM, Silvestri R, Barnhart C. Safety and diagnostic accuracy of adenosine thallium-201 scintigraphy in patients unable to exercise and those with left bundle branch block. Am Heart J 1992;124:614-21.

301. Iskandrian AS, Heo J, Lemlek J, et al. Identification of high-risk patients with left main and three-vessel coronary artery disease by adenosine-single photon emission computed tomographic thallium imaging. Am Heart J 1993;125:1130-5.

302. Mohiuddin SM, Ravage CK, Esterbrooks DJ, Lucas BD Jr, Hilleman DE. The comparative safety and diagnostic accuracy of adenosine myocardial perfusion imaging in women versus men. Pharmacotherapy 1996;16:646-51.

303. Amanullah AM, Berman DS, Hachamovitch R, Kiat H, Kang X, Friedman JD. Identification of severe or extensive coronary artery disease in women by adenosine technetium-99m sestamibi SPECT. Am J Cardiol 1997;80:132-7.

304. Amanullah AM, Berman DS, Kiat H, Friedman JD. Usefulness of hemodynamic changes during adenosine infusion in predicting the diagnostic accuracy of adenosine technetium-99m sestamibi single-photon emission computed tomography (SPECT). Am J Cardiol 1997;79:1319-22.

305. Wang FP, Amanullah AM, Kiat H, Friedman JD, Berman DS. Diagnostic efficacy of stress technetium 99m-labeled sestamibi myocardial perfusion single-photon emission computed tomography in detection of coronary artery disease among patients over age 80. J Nucl Cardiol 1995;2:380-8.

306. Samuels B, Kiat H, Friedman JD, Berman DS. Adenosine pharmacologic stress myocardial perfusion tomographic imaging in patients with significant aortic stenosis: diagnostic efficacy and comparison of clinical, hemodynamic and electrocardiographic variables with 100 age-matched control subjects. J Am Coll Cardiol 1995;25:99-106.

307. Sawada SG, Segar DS, Ryan T, et al. Echocardiographic detection of coronary artery disease during dobutamine infusion. Circulation 1991;83:1605-14.

308. Marcovitz PA, Armstrong WF. Accuracy of dobutamine stress echocardiography in detecting coronary artery disease. Am J Cardiol 1992;69:1269-73.

309. Takeuchi M, Araki M, Nakashima Y, Kuroiwa A. Comparison of dobutamine stress echocardiography and stress thallium-201 single-photon emission computed tomography for detecting coronary artery disease. J Am Soc Echocardiogr 1993;6:593-602.

310. Baudhuin T, Marwick T, Melin J, Wijns W, D’Hondt AM, Detry JM. Diagnosis of coronary artery disease in elderly patients: safety and efficacy of dobutamine echocardiography. Eur Heart J 1993;14:799-803.

311. Ostojic M, Picano E, Beleslin B, et al. Dipyridamole-dobutamine echocardiography: a novel test for the detection of milder forms of coronary artery disease. J Am Coll Cardiol 1994;23:1115-22.

312. Pingitore A, Picano E, Colosso MQ, et al. The atropine factor in pharmacologic stress echocardiography. Echo Persantine (EPIC) and Echo Dobutamine International Cooperative (EDIC) Study Groups. J Am Coll Cardiol 1996;27:1164-70.

313. Wu CC, Ho YL, Kao SL, et al. Dobutamine stress echocardiography for detecting coronary artery disease. Cardiology 1996;87:244-9.

314. Hennessy TG, Codd MB, Hennessy MS, et al. Comparison of dobutamine stress echocardiography and treadmill exercise electrocardiography for detection of coronary artery disease. Coron Artery Dis 1997;8:689-95.

315. Dionisopoulos PN, Collins JD, Smart SC, Knickelbine TA, Sagar KB. The value of dobutamine stress echocardiography for the detection of coronary artery disease in women. J Am Soc Echocardiogr 1997;10:811-7.

316. Elhendy A, Geleijnse ML, van Domburg RT, et al. Gender differences in the accuracy of dobutamine stress echocardiography for the diagnosis of coronary artery disease. Am J Cardiol 1997;80:1414-8.

317. Hennessy TG, Codd MB, McCarthy C, Kane G, McCann HA, Sugrue DD. Dobutamine stress echocardiography in the detection of coronary artery disease in a clinical practice setting. Int J Cardiol 1997;62:55-62.

318. Cohen JL, Ottenweller JE, George AK, Duvvuri S. Comparison of dobutamine and exercise echocardiography for detecting coronary artery disease. Am J Cardiol 1993;72:1226-31.

319. Marwick TH, D’Hondt AM, Mairesse GH, et al. Comparative ability of dobutamine and exercise stress in inducing myocardial ischaemia in active patients [published erratum appears in Br Heart J 1994;72:590]. Br Heart J 1994;72:31-8.

320. Cecil MP, Kosinski AS, Jones MT, et al. The importance of workup (verification) bias correction in assessing the accuracy of SPECT thallium-201 testing for the diagnosis of coronary artery disease. J Clin Epidemiol 1996;49:735-42.

321. Santana-Boado C, Candell-Riera J, Castell-Conesa J, et al. Diagnostic accuracy of technetium-99m-MIBI myocardial SPECT in women and men. J Nucl Med 1998;39:751-5.

322. Harding MB, Leithe ME, Mark DB, et al. Ergonovine maleate testing during cardiac catheterization: a 10-year perspective in 3,447 patients without significant coronary artery disease or Prinzmetal’s variant angina [published erratum appears in J Am Coll Cardiol 1993;21:848]. J Am Coll Cardiol 1992;20:107-11.

323. Mark DB, Califf RM, Morris KG, et al. Clinical characteristics and long-term survival of patients with variant angina. Circulation 1984;69:880-8.

324. Hillis LD, Braunwald E. Coronary-artery spasm. N Engl J Med 1978;299:695-702.

325. Roberts WC. Major anomalies of coronary arterial origin seen in adulthood. Am Heart J 1986;111:941-63.

326. Serota H, Barth CW, Seuc CA, Vandormael M, Aguirre F, Kern MJ. Rapid identification of the course of anomalous coronary arteries in adults: the “dot and eye” method. Am J Cardiol 1990;65:891-8.

327. Burks JM, Rothrock DR. Anomalous right coronary artery from the left sinus of Valsalva: demonstration of extensive collateral circulation. Cathet Cardiovasc Diagn 1996;39:67-70.

328. Hamada S, Yoshimura N, Takamiya M. Images in cardiovascular medicine: noninvasive imaging of anomalous origin of the left coronary artery from the pulmonary artery. Circulation 1998;97:219.

329. Burns JC, Shike H, Gordon JB, Malhotra A, Schoenwetter M, Kawasaki T. Sequelae of Kawasaki disease in adolescents and young adults. J Am Coll Cardiol 1996;28:253-7.

330. DeMaio SJ, Kinsella SH, Silverman ME. Clinical course and long-term prognosis of spontaneous coronary artery dissection. Am J Cardiol 1989;64:471-4.

331. Om A, Ellahham S, Vetrovec GW. Radiation-induced coronary artery disease. Am Heart J 1992;124:1598-602.

332. Proudfit WL, Shirey EK, Sones FM Jr. Selective cine coronary arteriography. Correlation with clinical findings in 1,000 patients. Circulation 1966;33:901-10.

333. Douglas JS Jr, Hurst JW. Limitations of symptoms in the recognition of coronary atherosclerotic heart disease. In: Hurst JW, ed. Hurst’s the Heart. New York: McGraw Hill, 1979:3-12.

334. Welch CC, Proudfit WL, Sheldon WC. Coronary arteriographic findings in 1,000 women under age 50. Am J Cardiol 1975; 35:211-5.

335. Patterson RE, Eisner RL, Horowitz SF. Comparison of cost-effectiveness and utility of exercise ECG, single photon emission computed tomography, positron emission tomography, and coronary angiography for diagnosis of coronary artery disease. Circulation 1995;91:54-65.

336. Ambepityia G, Kopelman PG, Ingram D, Swash M, Mills PG, Timmis AD. Exertional myocardial ischemia in diabetes: a quantitative analysis of anginal perceptual threshold and the influence of autonomic function. J Am Coll Cardiol 1990;15:72-7.

337. Douglas PS, Ginsburg GS. The evaluation of chest pain in women. N Engl J Med 1996;334:1311-5.

338. Gibbons RJ. Exercise ECG testing with and without radionuclide studies. In: Wenger NK, Speroff L, Packard B, eds. Cardiovascular Health and Disease in Women. Greenwich, CT: Le Jacq Communications, 1993:73-80.

339. DeSanctis RW. Clinical manifestations of coronary artery disease: chest pain in women. In: Wenger NK, Speroff L, Packard B, eds. Cardiovascular Health and Disease in Women. Greenwich, CT: Le Jacq Communications, 1993:67-72.

340. Shaw LJ, Miller DD, Romeis JC, Kargl D, Younis LT, Chaitman BR. Gender differences in the noninvasive evaluation and management of patients with suspected coronary artery disease. Ann Intern Med 1994;120:559-66.

341. Mark DB, Shaw LK, DeLong ER, Califf RM, Pryor DB. Absence of sex bias in the referral of patients for cardiac catheterization. N Engl J Med 1994;330:1101-6.

342. Hachamovitch R, Berman DS, Kiat H, et al. Gender-related differences in clinical management after exercise nuclear testing. J Am Coll Cardiol 1995;26:1457-64.

343. Kurita A, Takase B, Uehata A, et al. Painless myocardial ischemia in elderly patients compared with middle-aged patients and its relation to treadmill testing and coronary hemodynamics. Clin Cardiol 1991;14:886-90.

344. LaCroix AZ, Guralnik JM, Curb JD, Wallace RB, Ostfeld AM, Hennekens CH. Chest pain and coronary heart disease mortality among older men and women in three communities. Circulation 1990;81:437-46.

345. Johnson LW, Lozner EC, Johnson S, et al. Coronary arteriography 1984-1987: a report of the Registry of the Society for Cardiac Angiography and Interventions. I. Results and complications. Cathet Cardiovasc Diagn 1989;17:5-10.

346. Bertrand ME, Lablanche JM, Tilmant PY, et al. Frequency of provoked coronary arterial spasm in 1,089 consecutive patients undergoing coronary arteriography. Circulation 1982;65:1299-306.

347. Song JK, Lee SJ, Kang DH, et al. Ergonovine echocardiography as a screening test for diagnosis of vasospastic angina before coronary angiography. J Am Coll Cardiol 1996;27:1156-61.

348. Wolf NM, Meister SG. Irreversible coronary occlusion and ergonovine [letter]. Circulation 1982;66:252.

349. Pepine CJ. Ergonovine echocardiography for coronary spasm: facts and wishful thinking. J Am Coll Cardiol 1996;27:1162-3.

350. Spaulding CM, Joly LM, Rosenberg A, et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N Engl J Med 1997;336:1629-33.

351. Hubbard BL, et al. Prospective evaluation of a clinical and exercise-test model for the prediction of left main coronary artery disease. Ann Intern Med 1993;118:81-90.

352. Mock MB, Ringqvist I, Fisher LD, et al. Survival of medically treated patients in the Coronary Artery Surgery Study (CASS) registry. Circulation 1982;66:562-8.

353. Weiner DA, McCabe CH, Ryan TJ. Identification of patients with left main and three vessel coronary disease with clinical and exercise test variables. Am J Cardiol 1980;46:21-7.

354. Weiner DA, Ryan TJ, McCabe CH, et al. Prognostic importance of a clinical profile and exercise test in medically treated patients with coronary artery disease. J Am Coll Cardiol 1984;3:772-9.

355. Hammermeister KE, DeRouen TA, Dodge HT. Variables predictive of survival in patients with coronary disease. Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations. Circulation 1979;59:421-30.

356. Block WJ Jr, Crumpacker EL, Dry TJ, Gage RP. Prognosis of angina pectoris: observations in 6,882 cases. JAMA 1952;150:259-64.

357. Ideker RE,Wagner GS, Ruth WK, et al. Evaluation of a QRS scoring system for estimating myocardial infarct size. II. Correlation with quantitative anatomic findings for anterior infarcts. Am J Cardiol 1982;49:1604-14.

358. European Coronary Surgery Study Group. Prospective randomized study of coronary artery bypass surgery in stable angina pectoris. Second interim report by the European Coronary Surgery Study Group. Lancet 1980;2:491-5.

359. Murphy ML, Hultgren HN, Detre K, Thomsen J, Takaro T. Treatment of chronic stable angina. A preliminary report of survival data of the randomized Veterans Administration cooperative study. N Engl J Med 1977;297:621-7.

360. Proudfit WJ, Bruschke AV, MacMillan JP, Williams GW, Sones FM Jr. Fifteen year survival study of patients with obstructive coronary artery disease. Circulation 1983;68:986-97.

361. Frank CW, Weinblatt E, Shapiro S. Angina pectoris in men. Prognostic significance of selected medical factors. Circulation 1973;47:509-17.

362. Ruberman W, Weinblatt E, Goldberg JD, Frank CW, Shapiro S, Chaudhary BS. Ventricular premature complexes in prognosis of angina. Circulation 1980;61:1172-82.

363. Detre K, Peduzzi P, Murphy M, et al. Effect of bypass surgery on survival in patients in low- and high-risk subgroups delineated by the use of simple clinical variables. Circulation 1981;63:1329-38.

364. Detrano R, Hsiai T, Wang S, et al. Prognostic value of coronary calcification and angiographic stenoses in patients undergoing coronary angiography. J Am Coll Cardiol 1996;27:285-90.

365. Henry WL, Ware J, Gardin JM, Hepner SI, McKay J, Weiner M. Echocardiographic measurements in normal subjects. Growthrelated changes that occur between infancy and early adulthood. Circulation 1978;57:278-85.

366. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-67.

367. Vuille C, Weyman AE. Left ventricle, I: general considerations, assessment of chamber size and function. In: Weyman AE, ed. Principles and Practice of Echocardiography. 2nd ed. Philadelphia: Lea & Febiger, 1994:575-624.

368. Stamm RB, Carabello BA, Mayers DL, Martin RP. Two-dimensional echocardiographic measurement of left ventricular ejection fraction: prospective analysis of what constitutes an adequate determination. Am Heart J 1982;104:136-44.

369. Amico AF, Lichtenberg GS, Reisner SA, Stone CK, Schwartz RG, Meltzer RS. Superiority of visual versus computerized echocardiographic estimation of radionuclide left ventricular ejection fraction. Am Heart J 1989;118:1259-65.

370. Oh JK, Ding ZP, Gersh BJ, Bailey KR, Tajik AJ. Restrictive left ventricular diastolic filling identifies patients with heart failure after acute myocardial infarction. J Am Soc Echocardiogr 1992;5:497-503.

371. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study. Ann Intern Med 1989;110:101-7.

372. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6.

373. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-52.

374. Smith VE, Schulman P, Karimeddini MK, White WB, Meeran MK, Katz AM. Rapid ventricular filling in left ventricular hypertrophy, II. Pathologic hypertrophy. J Am Coll Cardiol 1985;5:869-74.

375. Bonow RO, Vitale DF, Bacharach SL, Maron BJ, Green MV. Effects of aging on asynchronous left ventricular regional function and global ventricular filling in normal human subjects. J Am Coll Cardiol 1988;11:50-8.

376. Borow KM, Neumann A, Wynne J. Sensitivity of end-systolic pressure-dimension and pressure-volume relations to the inotropic state in humans. Circulation 1982;65:988-97.

377. Martin ET, Fuisz AR, Pohost GM. Imaging cardiac structure and pump function. Cardiol Clin 1998;16:135-60.

378. Parisi AF, Moynihan PF, Folland ED, Strauss WE, Sharma GV, Sasahara AA. Echocardiography in acute and remote myocardial infarction. Am J Cardiol 1980;46:1205-14.

379. Shen W, Khandheria BK, Edwards WD, et al. Value and limitations of two-dimensional echocardiography in predicting myocardial infarct size. Am J Cardiol 1991;68:1143-9.

380. Oh JK, Gibbons RJ, Christian TF, et al. Correlation of regional wall motion abnormalities detected by two-dimensional echocardiography with perfusion defect determined by technetium 99m sestamibi imaging in patients treated with reperfusion therapy during acute myocardial infarction. Am Heart J 1996;131:32-7.

381. Visser CA, Lie KI, Kan G, Meltzer R, Durrer D. Detection and quantification of acute, isolated myocardial infarction by two dimensional echocardiography. Am J Cardiol 1981;47:1020-5.

382. Horowitz RS, Morganroth J. Immediate detection of early highrisk patients with acute myocardial infarction using two-dimensional echocardiographic evaluation of left ventricular regional wall motion abnormalities. Am Heart J 1982;103:814-22.

383. Bhatnagar SK, Moussa MA, Al-Yusuf AR. The role of prehospital discharge two-dimensional echocardiography in determining the prognosis of survivors of first myocardial infarction. Am Heart J 1985;109:472-7.

384. Nelson GR, Cohn PF, Gorlin R. Prognosis in medically-treated coronary artery disease: influence of ejection fraction compared to other parameters. Circulation 1975;52:408-12.

385. Weyman AE, Peskoe SM, Williams ES, Dillon JC, Feigenbaum H. Detection of left ventricular aneurysms by cross-sectional echocardiography. Circulation 1976;54:936-44.

386. Visser CA, Kan G, David GK, Lie KI, Durrer D. Echocardiographic-cineangiographic correlation in detecting left ventricular aneurysm: a prospective study of 422 patients. Am J Cardiol 1982;50:337-41.

387. Barrett MJ, Charuzi Y, Corday E. Ventricular aneurysm: crosssectional echocardiographic approach. Am J Cardiol 1980;46:1133-7.

388. Keren A, Goldberg S, Gottlieb S, et al. Natural history of left ventricular thrombi: their appearance and resolution in the posthospitalization period of acute myocardial infarction. J Am Coll Cardiol 1990;15:790-800.

389. Visser CA, Kan G, Meltzer RS, Dunning AJ, Roelandt J. Embolic potential of left ventricular thrombus after myocardial infarction: a two-dimensional echocardiographic study of 119 patients. J Am Coll Cardiol 1985;5:1276-80.

390. DeMaria AN, Bommer W, Neumann A, et al. Left ventricular thrombi identified by cross-sectional echocardiography. Ann Intern Med 1979;90:14-8.

391. Spirito P, Bellotti P, Chiarella F, Domenicucci S, Sementa A, Vecchio C. Prognostic significance and natural history of left ventricular thrombi in patients with acute anterior myocardial infarction: a two-dimensional echocardiographic study. Circulation 1985;72:774-80.

392. Gueret P, Dubourg O, Ferrier A, Farcot JC, Rigaud M, Bourdarias JP. Effects of full-dose heparin anticoagulation on the development of left ventricular thrombosis in acute transmural myocardial infarction. J Am Coll Cardiol 1986;8:419-26.

393. Keating EC, Gross SA, Schlamowitz RA, et al. Mural thrombi in myocardial infarctions. Prospective evaluation by two-dimensional echocardiography. Am J Med 1983;74:989-95.

394. Stratton JR, Lighty GW, Pearlman AS, Ritchie JL. Detection of left ventricular thrombus by two-dimensional echocardiography: sensitivity, specificity, and causes of uncertainty. Circulation 1982;66:156-66.

395. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 1993;22:2033-54.

396. Rihal CS, Davis KB, Kennedy JW, Gersh BJ. The utility of clinical, electrocardiographic, and roentgenographic variables in the prediction of left ventricular function. Am J Cardiol 1995;75:220-3.

397. Christian TF, Miller TD, Bailey KR, Gibbons RJ. Exercise tomographic thallium-201 imaging in patients with severe coronary artery disease and normal electrocardiograms. Ann Intern Med 1994;121:825-32.

398. Gibbons RJ, Zinsmeister AR, Miller TD, Clements IP. Supine exercise electrocardiography compared with exercise radionuclide angiography in noninvasive identification of severe coronary artery disease. Ann Intern Med 1990;112:743-9.

399. Mattera JA, Arain SA, Sinusas AJ, Finta L, Wackers FJ III. Exercise testing with myocardial perfusion imaging in patients with normal baseline electrocardiograms: cost savings with a stepwise diagnostic strategy. J Nucl Cardiol 1998;5:498-506.

400. Ladenheim ML, Kotler TS, Pollock BH, Berman DS, Diamond GA. Incremental prognostic power of clinical history, exercise electrocardiography and myocardial perfusion scintigraphy in suspected coronary artery disease. Am J Cardiol 1987;59:270-7.

401. Mark DB, Hlatky MA, Harrell FE, Lee KL, Califf RM, Pryor DB. Exercise treadmill score for predicting prognosis in coronary artery disease. Ann Intern Med 1987;106:793-800.

402. Morrow K, Morris CK, Froelicher VF, et al. Prediction of cardiovascular death in men undergoing noninvasive evaluation for coronary artery disease. Ann Intern Med 1993;118:689-95.

403. Brunelli C, Cristofani R, L’Abbate A. Long-term survival in medically treated patients with ischaemic heart disease and prognostic importance of clinical and electrocardiographic data (the Italian CNR Multicentre Prospective Study OD1). Eur Heart J 1989;10:292-303.

404. Luwaert RJ, Melin JA, Brohet CR, et al. Non-invasive data provide independent prognostic information in patients with chest pain without previous myocardial infarction: findings in male patients who have had cardiac catheterization. Eur Heart J 1988;9:418-26.

405. Gohlke H, Samek L, Betz P, Roskamm H. Exercise testing provides additional prognostic information in angiographically defined subgroups of patients with coronary artery disease. Circulation 1983;68:979-85.

406. Smith RF, Johnson G, Ziesche S, Bhat G, Blankenship K, Cohn JN. Functional capacity in heart failure. Comparison of methods for assessment and their relation to other indexes of heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87:VI88-93.

407. Nallamothu N, Ghods M, Heo J, Iskandrian AS. Comparison of thallium-201 single-photon emission computed tomography and electrocardiographic response during exercise in patients with normal rest electrocardiographic results. J Am Coll Cardiol 1995;25:830-6.

408. Simari RD, Miller TD, Zinsmeister AR, Gibbons RJ. Capabilities of supine exercise electrocardiography versus exercise radionuclide angiography in predicting coronary events. Am J Cardiol 1991;67:573-7.

409. Bruce RA, DeRouen TA, Hossack KF. Pilot study examining the motivational effects of maximal exercise testing to modify risk factors and health habits. Cardiology 1980;66:111-9.

410. Hachamovitch R, Berman DS, Kiat H, et al. Exercise myocardial perfusion SPECT in patients without known coronary artery disease: incremental prognostic value and use in risk stratification. Circulation 1996;93:905-14.

411. Hecht HS, Shaw RE, Chin HL, Ryan C, Stertzer SH, Myler RK. Silent ischemia after coronary angioplasty: evaluation of restenosis and extent of ischemia in asymptomatic patients by tomographic thallium-201 exercise imaging and comparison with symptomatic patients. J Am Coll Cardiol 1991;17:670-7.

412. Hecht HS, DeBord L, Shaw R, et al. Usefulness of supine bicycle stress echocardiography for detection of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1993;71:293-6.

413. Pepine CJ, Cohn PF, Deedwania PC, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation 1994;90:762-8.

414. Knatterud GL, Bourassa MG, Pepine CJ, et al. Effects of treatment strategies to suppress ischemia in patients with coronary artery disease: 12-week results of the Asymptomatic Cardiac Ischemia Pilot (ACIP) study. J Am Coll Cardiol 1994;24:11-20.

415. Bonow RO. Diagnosis and risk stratification in coronary artery disease: nuclear cardiology versus stress echocardiography. J Nucl Cardiol 1997;4:S172-8.

416. Marcovitz PA. Prognostic issues in stress echocardiography. Prog Cardiovasc Dis 1997;39:533-42.

417. Boyne TS, Koplan BA, Parsons WJ, Smith WH, Watson DD, Beller GA. Predicting adverse outcome with exercise SPECT technetium-99m sestamibi imaging in patients with suspected or known coronary artery disease. Am J Cardiol 1997;79:270-4.

418. Leppo JA. Comparison of pharmacologic stress agents. J Nucl Cardiol 1996;3:S22-6.

419. Kiat H, Maddahi J, Roy LT, et al. Comparison of technetium 99m methoxy isobutyl isonitrile and thallium 201 for evaluation of coronary artery disease by planar and tomographic methods. Am Heart J 1989;117:1-11.

420. Sawada SG, Ryan T, Conley MJ, Corya BC, Feigenbaum H, Armstrong WF. Prognostic value of a normal exercise echocardiogram. Am Heart J 1990;120:49-55.

421. Krivokapich J, Child JS, Gerber RS, Lem V, Moser D. Prognostic usefulness of positive or negative exercise stress echocardiography for predicting coronary events in ensuing twelve months. Am J Cardiol 1993;71:646-51.

422. Mazeika PK, Nadazdin A, Oakley CM. Prognostic value of dobutamine echocardiography in patients with high pretest likelihood of coronary artery disease. Am J Cardiol 1993;71:33-9.

423. Severi S, Picano E, Michelassi C, et al. Diagnostic and prognostic value of dipyridamole echocardiography in patients with suspected coronary artery disease. Comparison with exercise electrocardiography. Circulation 1994;89:1160-73.

424. Coletta C, Galati A, Greco G, et al. Prognostic value of high dose dipyridamole echocardiography in patients with chronic coronary artery disease and preserved left ventricular function. J Am Coll Cardiol 1995;26:887-94.

425. Williams MJ, Odabashian J, Lauer MS, Thomas JD,Marwick TH. Prognostic value of dobutamine echocardiography in patients with left ventricular dysfunction. J Am Coll Cardiol 1996;27:132- 9.

426. Afridi I, Quinones MA, Zoghbi WA, Cheirif J. Dobutamine stress echocardiography: sensitivity, specificity, and predictive value for future cardiac events. Am Heart J 1994;127:1510-5.

427. Kamaran M, Teague SM, Finkelhor RS, Dawson N, Bahler RC. Prognostic value of dobutamine stress echocardiography in patients referred because of suspected coronary artery disease. Am J Cardiol 1995;76:887-91.

428. Marcovitz PA, Shayna V, Horn RA, Hepner A, Armstrong WF. Value of dobutamine stress echocardiography in determining the prognosis of patients with known or suspected coronary artery disease. Am J Cardiol 1996;78:404-8.

429. Brown KA. Prognostic value of thallium-201 myocardial perfusion imaging: a diagnostic tool comes of age. Circulation 1991;83:363-81.

430. National Center for Health Statistics. Vital Statistics of the United States, 1979, Vol II: Mortality, Part A. Washington, DC: US Government Printing Office; 1984. US Department of Health and Human Services publication (PHS) 84-1101.

431. Hachamovitch R, Berman DS, Shaw LJ, et al. Incremental prognostic value of myocardial perfusion SPECT for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction [published erratum appears in Circulation 1998;98:120]. Circulation 1998;97:533-43.

432. Boucher CA, Zir LM, Beller GA, et al. Increased lung uptake of thallium-201 during exercise myocardial imaging: clinical, hemodynamic and angiographic implications in patients with coronary artery disease. Am J Cardiol 1980;46:189-96.

433. Nishimura S, Mahmarian JJ,Verani MS. Significance of increased lung thallium uptake during adenosine thallium-201 scintigraphy. J Nucl Med 1992;33:1600-7.

434. Beller GA. Radionuclide perfusion imaging techniques for evaluation of patients with known or suspected coronary artery disease. Adv Intern Med 1997;42:139-201.

435. Cox JL, Wright LM, Burns RJ. Prognostic significance of increased thallium-201 lung uptake during dipyridamole myocardial scintigraphy: comparison with exercise scintigraphy. Can J Cardiol 1995;11:689-94.

436. Weiss AT, Berman DS, Lew AS, et al. Transient ischemic dilation of the left ventricle on stress thallium-201 scintigraphy: a marker of severe and extensive coronary artery disease. J Am Coll Cardiol 1987;9:752-9.

437. Krawczynska EG, Weintraub WS, Garcia EV, Folks RD, Jones ME, Alazraki NP. Left ventricular dilatation and multivessel coronary artery disease on thallium-201 SPECT are important prognostic indicators in patients with large defects in the left anterior descending distribution. Am J Cardiol 1994;74:1233-9.

438. Veilleux M, Lette J, Mansur A, et al. Prognostic implications of transient left ventricular cavitary dilation during exercise and dipyridamole-thallium imaging. Can J Cardiol 1994;10:259-62.

439. McClellan JR, Travin MI, Herman SD, et al. Prognostic importance of scintigraphic left ventricular cavity dilation during intravenous dipyridamole technetium-99m sestamibi myocardial tomographic imaging in predicting coronary events. Am J Cardiol 1997;79:600-5.

440. Brown KA, Boucher CA, Okada RD, et al. Prognostic value of exercise thallium-201 imaging in patients presenting for evaluation of chest pain. J Am Coll Cardiol 1983;1:994-1001.

441. Ladenheim ML, Pollock BH, Rozanski A, et al. Extent and severity of myocardial hypoperfusion as predictors of prognosis in patients with suspected coronary artery disease. J Am Coll Cardiol 1986;7:464-71.

442. Hendel RC, Layden JJ, Leppo JA. Prognostic value of dipyridamole thallium scintigraphy for evaluation of ischemic heart disease. J Am Coll Cardiol 1990;15:109-16.

443. Iskandrian AS, Heo J, Decoskey D, Askenase A, Segal BL. Use of exercise thallium-201 imaging for risk stratification of elderly patients with coronary artery disease. Am J Cardiol 1988;61:269-72.

444. Kaul S, Lilly DR, Gascho JA, et al. Prognostic utility of the exercise thallium-201 test in ambulatory patients with chest pain: comparison with cardiac catheterization. Circulation 1988; 77:745-58.

445. Staniloff HM, Forrester JS, Berman DS, Swan HJ. Prediction of death, myocardial infarction, and worsening chest pain using thallium scintigraphy and exercise electrocardiography. J Nucl Med 1986;27:1842-8.

446. Stratmann HG, Mark AL, Walter KE, Williams GA. Prognostic value of atrial pacing and thallium-201 scintigraphy in patients with stable chest pain. Am J Cardiol 1989;64:985-90.

447. Younis LT, Byers S, Shaw L, Barth G, Goodgold H, Chaitman BR. Prognostic importance of silent myocardial ischemia detected by intravenous dipyridamole thallium myocardial imaging in asymptomatic patients with coronary artery disease. J Am Coll Cardiol 1989;14:1635-41.

448. Berman DS, Hachamovitch R. Risk assessment in patients with stable coronary artery disease: incremental value of nuclear imaging. J Nucl Cardiol 1996;3:S41-9.

449. Gioia G, Milan E, Giubbini R, DePace N, Heo J, Iskandrian AS. Prognostic value of tomographic rest-redistribution thallium 201 imaging in medically treated patients with coronary artery disease and left ventricular dysfunction. J Nucl Cardiol 1996;3:150-6.

450. Kaul S, Finkelstein DM, Homma S, Leavitt M, Okada RD, Boucher CA. Superiority of quantitative exercise thallium-201 variables in determining long-term prognosis in ambulatory patients with chest pain: a comparison with cardiac catheterization. J Am Coll Cardiol 1988;12:25-34.

451. Iskandrian AS, Chae SC, Heo J, Stanberry CD, Wasserleben V, Cave V. Independent and incremental prognostic value of exercise single-photon emission computed tomographic (SPECT) thallium imaging in coronary artery disease. J Am Coll Cardiol 1993;22:665-70.

452. Gill JB, Ruddy TD, Newell JB, Finkelstein DM, Strauss HW, Boucher CA. Prognostic importance of thallium uptake by the lungs during exercise in coronary artery disease. N Engl J Med 1987;317:1486-9.

453. Borges-Neto S, Coleman RE, Potts JM, Jones RH. Combined exercise radionuclide angiocardiography and single photon emission computed tomography perfusion studies for assessment of coronary artery disease. Semin Nucl Med 1991;21:223-9.

454. Pollock SG, Abbott RD, Boucher CA, Beller GA, Kaul S. Independent and incremental prognostic value of tests performed in hierarchical order to evaluate patients with suspected coronary artery disease: validation of models based on these tests. Circulation 1992;85:237-40.

455. Machecourt J, Longere P, Fagret D, et al. Prognostic value of thallium-201 single-photon emission computed tomographic myocardial perfusion imaging according to extent of myocardial defect. J Am Coll Cardiol 1994;23:1096-106.

456. Marie YP, Danchin N, Durand JF, et al. Long-term prediction of major ischemic events by exercise thallium-201 single-photon emission computed tomography. J Am Coll Cardiol 1995;26:879-86.

457. Geleijnse ML, Elhendy A, van Domburg RT, et al. Prognostic value of dobutamine-atropine stress technetium-99m sestamibi perfusion scintigraphy in patients with chest pain. J Am Coll Cardiol 1996;28:447-54.

458. Kamal AM, Fattah AA, Pancholy S, et al. Prognostic value of adenosine single-photon emission computed tomographic thallium imaging in medically treated patients with angiographic evidence of coronary artery disease. J Nucl Cardiol 1994;1:254-61.

459. Stratmann HG, Tamesis BR, Younis LT, Wittry MD, Miller DD. Prognostic value of dipyridamole technetium-99m sestamibi myocardial tomography in patients with stable chest pain who are unable to exercise. Am J Cardiol 1994;73:647-52.

460. Stratmann HG, Williams GA, Wittry MD, Chaitman BR, Miller DD. Exercise technetium-99m sestamibi tomography for cardiac risk stratification of patients with stable chest pain. Circulation 1994;89:615-22.

461. Iskandrian AS, Hakki AH, Kane-Marsch S. Prognostic implications of exercise thallium-201 scintigraphy in patients with suspected or known coronary artery disease. Am Heart J 1985;110:135-43.

462. Aoki M, Sakai K, Koyanagi S, Takeshita A, Nakamura M. Effect of nitroglycerin on coronary collateral function during exercise evaluated by quantitative analysis of thallium-201 single photon emission computed tomography. Am Heart J 1991;121:1361-6.

463. Wagdy HM, Hodge D, Christian TF, Miller TD, Gibbons RJ. Prognostic value of vasodilator myocardial perfusion imaging in patients with left bundle branch block. Circulation 1998;97:1563-70.

464. Nallamothu N, Bagheri B, Acio ER, Heo J, Iskandrian AE. Prognostic value of stress myocardial perfusion single photon emission computed tomography imaging in patients with left ventricular bundle branch block. J Nucl Cardiol 1997;4:487-93.

465. Nigam A, Humen DP. Prognostic value of myocardial perfusion imaging with exercise and/or dipyridamole hyperemia in patients with preexisting left bundle branch block. J Nucl Med 1998;39:579-81.

466. Gil VM, Almeida M, Ventosa A, et al. Prognosis in patients with left bundle branch block and normal dipyridamole thallium-201 scintigraphy. J Nucl Cardiol 1998;5:414-7.

467. Kostkiewicz M, Jarosz W, Tracz W, et al. Thallium-201 myocardial perfusion imaging in patients before and after successful percutaneous transluminal coronary angioplasty. Int J Cardiol 1996;53:299-304.

468. Zhao XQ, Brown BG, Stewart DK, et al. Effectiveness of revascularization in the Emory Angioplasty versus Surgery Trial. A randomized comparison of coronary angioplasty with bypass surgery. Circulation 1996;93:1954-62.

469. Lewis BS, Hardoff R, Merdler A, et al. Importance of immediate and very early postprocedural angiographic and thallium-201 single photon emission computed tomographic perfusion measurements in predicting late results after coronary intervention. Am Heart J 1995;130:425-32.

470. Ritchie JL, Narahara KA, Trobaugh GB, Williams DL, Hamilton GW. Thallium-201 myocardial imaging before and after coronary revascularization: assessment of regional myocardial blood flow and graft patency. Circulation 1977;56:830-6.

471. Verani MS, Marcus ML, Spoto G, Rossi NP, Ehrhardt JC, Razzak MA. Thallium-201 myocardial perfusion scintigrams in the evaluation of aorto-coronary saphenous surgery. J Nucl Med 1978;19:765-72.

472. Miller TD, Christian TF, Hodge DO, Mullan BP, Gibbons RJ. Prognostic value of exercise thallium-201 imaging performed within 2 years of coronary artery bypass graft surgery. J Am Coll Cardiol 1998;31:848-54.

473. Palmas W, Bingham S, Diamond GA, et al. Incremental prognostic value of exercise thallium-201 myocardial single-photon emission computed tomography late after coronary artery bypass surgery. J Am Coll Cardiol 1995;25:403-9.

474. Lauer MS, Lytle B, Pashkow F, Snader CE, Marwick TH. Prediction of death and myocardial infarction by screening with exercise-thallium testing after coronary-artery-bypass grafting. Lancet 1998;351:615-22.

475. Nallamothu N, Johnson JH, Bagheri B, Heo J, Iskandrian AE. Utility of stress single-photon emission computed tomography (SPECT) perfusion imaging in predicting outcome after coronary artery bypass grafting. Am J Cardiol 1997;80:1517-21.

476. McCully RB, Roger VL, Mahoney DW, et al. Outcome after normal exercise echocardiography and predictors of subsequent cardiac events: follow-up of 1,325 patients. J Am Coll Cardiol 1998;31:144-9.

477. Marwick T, D’Hondt AM, Baudhuin T, et al. Optimal use of dobutamine stress for the detection and evaluation of coronary artery disease: combination with echocardiography or scintigraphy, or both? J Am Coll Cardiol 1993;22:159-67.

478. Marwick TH. Use of stress echocardiography for the prognostic assessment of patients with stable chronic coronary artery disease. Eur Heart J 1997;18(Suppl D):D97-101.

479. Heupler S, Mehta R, Lobo A, Leung D, Marwick TH. Prognostic implications of exercise echocardiography in women with known or suspected coronary artery disease. J Am Coll Cardiol 1997;30:414-20.

480. Marwick TH, Mehta R, Arheart K, Lauer MS. Use of exercise echocardiography for prognostic evaluation of patients with known or suspected coronary artery disease. J Am Coll Cardiol 1997;30:83-90.

481. Chuah SC, Pellikka PA, Roger VL, McCully RB, Seward JB. Role of dobutamine stress echocardiography in predicting outcome in 860 patients with known or suspected coronary artery disease. Circulation 1998;97:1474-80.

482. AIMS Trial Study Group. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. Lancet 1990;335:427-31.

483. Truett J, Cornfield J, Kannel W. A multivariate analysis of the risk of coronary heart disease in Framingham. J Chronic Dis 1967;20:511-24.

484. Hlatky MA, Califf RM, Harrell FE, et al. Clinical judgment and therapeutic decision making. J Am Coll Cardiol 1990;15:1-14.

485. Califf RM, Armstrong PW, Carver JR, D’Agostino RB, Strauss WE. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. J Am Coll Cardiol 1996;27:1007-19.

486. Ambrose JA, Fuster V. Can we predict future acute coronary events in patients with stable coronary artery disease? JAMA 1997;277:343-4.

487. Daley J, Shwartz M. Developing risk-adjustment methods. In: Iezzone LI, ed. Risk Adjustment for Measuring Health Care Outcomes. Ann Arbor, MI: Health Administration Press, 1994:199-238.

488. Emond M, Mock MB, Davis KB, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation 1994;90:2645-57.

489. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration [published erratum appears in Lancet 1994;344:1446]. Lancet 1994;344:563-70.

490. Topol EJ, Nissen SE. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation 1995;92:2333-42.

491. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-71.

492. Mann JM, Davies MJ. Vulnerable plaque. Relation of characteristics to degree of stenosis in human coronary arteries. Circulation 1996;94:928-31.

493. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-50.

494. Fuster V, Fallon JT, Nemerson Y. Coronary thrombosis. Lancet 1996;348(Suppl 1):S7-10.

495. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988;12:56-62.

496. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988;78:1157-66.

497. Ringqvist I, Fisher LD, Mock M, Davis KB, et al. Prognostic value of angiographic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS). J Clin Invest 1983;71:1854-66.

498. The Veterans Administration Coronary Artery Bypass Cooperative Study Group. Eleven year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. N Engl J Med 1984;311:1333-9.

499. Alderman EL, Bourassa MG, Cohen LS, et al. Ten-year follow-up of survival and myocardial infarction in the randomized Coronary Artery Surgery Study. Circulation 1990;82:1629-46.

500. Gersh BJ, Califf RM, Loop FD, Akins CW, Pryor DB, Takaro TC. Coronary bypass surgery in chronic stable angina. Circulation 1989;79:I46-59.

501. Mark DB, Nelson CL, Califf RM, et al. Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. Circulation 1994;89:2015-25.

502. Califf RM, Phillips HRI, Hindman MC, et al. Prognostic value of a coronary artery jeopardy score. J Am Coll Cardiol 1985;5:1055-63.

503. Nakagomi A, Celermajer DS, Lumley T, Freedman SB. Angiographic severity of coronary narrowing is a surrogate marker for the extent of coronary atherosclerosis. Am J Cardiol 1996;78:516-9.

504. Toussaint JF, LaMuraglia GM, Southern JF, Fuster V, Kantor HL. Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. Circulation 1996;94:932-8.

505. Waller BF, Rothbaum DA, Gorfinkel HJ, Ulbright TM, Linnemeier TJ, Berger SM. Morphologic observations after percutaneous transluminal balloon angioplasty of early and late aortocoronary saphenous vein bypass grafts. J Am Coll Cardiol 1984;4:784-92.

506. Neitzel GF, Barboriak JJ, Pintar K, Qureshi I. Atherosclerosis in aortocoronary bypass grafts: morphologic study and risk factor analysis 6 to 12 years after surgery. Arteriosclerosis 1986;6:594-600.

507. Walts AE, Fishbein MC, Sustaita H, Matloff JM. Ruptured atheromatous plaques in saphenous vein coronary artery bypass grafts: a mechanism of acute, thrombotic, late graft occlusion. Circulation 1982;65:197-201.

508. Tilli FV, Kaplan BM, Safian RD, et al. Angioscopic plaque friability: a new risk factor for procedural complications following saphenous vein graft interventions (abstract). J Am Coll Cardiol 1996;27(Suppl A):364A.

509. Lytle BW, Loop FD, Taylor PC, et al. The effect of coronary reoperation on the survival of patients with stenoses in saphenous vein bypass grafts to coronary arteries. J Thorac Cardiovasc Surg 1993;105:605-12.

510. Lytle BW, Loop FD, Taylor PC, et al. Vein graft disease: the clinical impact of stenoses in saphenous vein bypass grafts to coronary arteries. J Thorac Cardiovasc Surg 1992;103:831-40.

511. Savage MP, Douglas JS Jr, Fischman DL, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med 1997;337:740-7.

512. Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Ann Intern Med 1991;114:835-9.

513. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1995;308:81-106.

514. Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309:396-403.

515. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985;313:1369-75.

516. Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989;321:129-35.

517. Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992;340:1421-5.

518. McTavish D, Faulds D, Goa KL. Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 1990;40:238-59.

519. Ticlopidine [editorial]. Lancet 1991;337:459-60.

520. de Maat MP, Arnold AE, van Buuren S, Wilson JH, Kluft C. Modulation of plasma fibrinogen levels by ticlopidine in healthy volunteers and patients with stable angina pectoris. Thromb Haemost 1996;76:166-70.

521. Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G. Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects. Chest 1995;108:247S-57S.

522. Cimminiello D, Agugua F, et al. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. Circulation 1990;82:17-26.

523. Savi P, Laplace MC, Maffrand JP, Herbert JM. Binding of [3H]-2-methylthio ADP to rat platelets-effect of clopidogrel and ticlopidine J Pharmacol Exp Ther 1994;269:772-7.

524. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.

525. Gresele P, Arnout J, Deckmyn H, Vermylen J. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb Haemost 1986;55:12-8.

526. Tsuya T, Okada M, Horie H, Ishikawa K. Effect of dipyridamole at the usual oral dose on exercise-induced myocardial ischemia in stable angina pectoris. Am J Cardiol 1990;66:275-8.

527. Held C, Hjemdahl P, Rehnqvist N, et al. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm. Circulation 1997;95:2380-6.

528. Melandri G, Semprini F, Cervi V, et al. Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris. A double-blind, randomized, placebo-controlled trial. Circulation 1993;88:2517-23.

529. van den Bos AA, Deckers JW, Heyndrickx GR, et al. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 1993;88:2058-66.

530. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework. Lancet 1998;351:233-41.

531. Larosa JC, Hunninghake D, Bush D, et al. The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation 1990;81:1721-33.

532. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998;97:946-52.

533. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.

534. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.

535. Frishman WH, Heiman M, Soberman J, Greenberg S, Eff J. Comparison of celiprolol and propranolol in stable angina pectoris. Celiprolol International Angina Study Group. Am J Cardiol 1991;67:665-70.

536. Narahara KA. Double-blind comparison of once daily betaxolol versus propranolol four times daily in stable angina pectoris. Betaxolol Investigators Group. Am J Cardiol 1990;65:577-82.

537. Hauf-Zachariou U, Blackwood RA, Gunawardena KA, O’Donnell JG, Garnham S, Pfarr E. Carvedilol versus verapamil in chronic stable angina: a multicentre trial. Eur J Clin Pharmacol 1997;52:95-100.

538. Raftery EB. The preventative effects of vasodilating beta-blockers in cardiovascular disease. Eur Heart J 1996;17(Suppl B):30-8.

539. McLenachan JM, Findlay IN,Wilson JT, Dargie HJ. Twenty-four hour beta-blockade in stable angina pectoris: a study of atenolol and betaxolol. J Cardiovasc Pharmacol 1992;20:311-5.

540. Prida XE, Hill JA, Feldman RL. Systemic and coronary hemodynamic effects of combined alpha- and beta-adrenergic blockade (labetalol) in normotensive patients with stable angina pectoris and positive exercise stress test responses. Am J Cardiol 1987;59:1084-8.

541. Capone P, Mayol R. Celiprolol in the treatment of exercise induced angina pectoris. J Cardiovasc Pharmacol 1986;8(Suppl 4):S135-7.

542. Ryden L. Efficacy of epanolol versus metoprolol in angina pectoris: report from a Swedish multicentre study of exercise tolerance. J Intern Med 1992;231:7-11.

543. Boberg J, Larsen FF, Pehrsson SK. The effects of beta blockade with (epanolol) and without (atenolol) intrinsic sympathomimetic activity in stable angina pectoris. The Visacor Study Group. Clin Cardiol 1992;15:591-5.

544. Wallace WA, Wellington KL, Chess MA, Liang CS. Comparison of nifedipine gastrointestinal therapeutic system and atenolol on antianginal efficacies and exercise hemodynamic responses in stable angina pectoris. Am J Cardiol 1994;73:23-8.

545. de Vries RJ, van den Heuvel AF, Lok DJ, et al. Nifedipine gastrointestinal therapeutic system versus atenolol in stable angina pectoris. The Netherlands Working Group on Cardiovascular Research (WCN). Int J Cardiol 1996;57:143-50.

546. Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ. The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Eur Heart J 1996;17:96-103.

547. van de Ven LL,Vermeulen A, Tans JG, et al. Which drug to choose for stable angina pectoris: a comparative study between bisoprolol and nitrates. Int J Cardiol 1995;47:217-23.

548. Gruppo Italiano per lo Studio della Sopravvivenza nell-infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.

549. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998;279:1903-7.

550. Waysbort J, Meshulam N, Brunner D. Isosorbide-5-mononitrate and atenolol in the treatment of stable exertional angina. Cardiology 1991;79(Suppl 2):19-26:19-26.

551. Krepp HP. Evaluation of the antianginal and anti-ischemic efficacy of slow-release isosorbide-5-mononitrate capsules, bupranolol and their combination, in patients with chronic stable angina pectoris. Cardiology 1991;79(Suppl 2):14-8.

552. Kawanishi DT, Reid CL, Morrison EC, Rahimtoola SH. Response of angina and ischemia to long-term treatment in patients with chronic stable angina: a double-blind randomized individualized dosing trial of nifedipine, propranolol and their combination. J Am Coll Cardiol 1992;19:409-17.

553. Meyer TE, Adnams C, Commerford P. Comparison of the efficacy of atenolol and its combination with slow-release nifedipine in chronic stable angina. Cardiovasc Drugs Ther 1993;7:909-13.

554. Steffensen R, Grande P, Pedersen F, Haunso S. Effects of atenolol and diltiazem on exercise tolerance and ambulatory ischaemia. Int J Cardiol 1993;40:143-53.

555. Parameshwar J, Keegan J, Mulcahy D, et al. Atenolol or nicardipine alone is as efficacious in stable angina as their combination: a double blind randomised trial. Int J Cardiol 1993;40:135-41.

556. Foale RA. Atenolol versus the fixed combination of atenolol and nifedipine in stable angina pectoris. Eur Heart J 1993;14:1369-74.

557. Tilmant PY, Lablanche JM, Thieuleux FA, Dupuis BA, Bertrand ME. Detrimental effect of propranolol in patients with coronary arterial spasm countered by combination with diltiazem. Am J Cardiol 1983;52:230-3.

558. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997;277:739-45.

559. Dargie HJ, Ford I, Fox KM. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Eur Heart J 1996;17:104-12.

560. Rehnqvist N, Hjemdahl P, Billing E, et al. Treatment of stable angina pectoris with calcium antagonists and beta-blockers. The APSIS study. Angina Prognosis Study in Stockholm. Cardiologia 1995;40(Suppl 1):301.

561. von Arnim T. Medical treatment to reduce total ischemic burden: Total Ischemic Burden Bisoprolol Study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators. J Am Coll Cardiol 1995;25:231-8.

562. Savonitto S, Ardissiono D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 1996;27:311-6.

563. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98:1184-91.

564. Bassan MM, Weiler-Ravell D, Shalev O. Comparison of the antianginal effectiveness of nifedipine, verapamil, and isosorbide dinitrate in patients receiving propranolol: a double-blind study. Circulation 1983;68:568-75.

565. Wassertheil-Smoller S, Oberman A, Blaufox MD, Davis B, Langford H. The Trial of Antihypertensive Interventions and Management (TAIM) Study: final results with regard to blood pressure, cardiovascular risk, and quality of life. Am J Hypertens 1992;5:37-44.

566. Bassan MM, Weiler-Ravell D. The additive antianginal action of oral isosorbide dinitrate in patients receiving propranolol. Magnitude and duration of effect. Chest 1983;83:233-40.

567. Braun S, van der Wall EE, Emanuelsson H, Kobrin I. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group. J Am Coll Cardiol 1996;27:317-22.

568. Bakx AL, van der Wall EE, Braun S, Emanuelsson H, Bruschke AV, Kobrin I. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group. Am Heart J 1995;130:748-57.

569. Brogden RN, Benfield P. Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease. Drugs 1996;51:792-819.

570. Glasser SP, Ripa S, Garland WT, et al. Antianginal and antiischemic efficacy of monotherapy extended-release nisoldipine (Coat Core) in chronic stable angina. J Clin Pharmacol 1995;35:780-4.

571. Boman K, Saetre H, Karlsson LG, et al. Antianginal effect of conventional and controlled release diltiazem in stable angina pectoris. Eur J Clin Pharmacol 1995;49:27-30.

572. Walker JM, Curry PV, Bailey AE, Steare SE. A comparison of nifedipine once daily (Adalat LA), isosorbide mononitrate once daily, and isosorbide dinitrate twice daily in patients with chronic stable angina. Int J Cardiol 1996;53:117-26.

573. Ezekowitz MD, Hossack K, Mehta JL, et al. Amlodipine in chronic stable angina: results of a multicenter double-blind crossover trial. Am Heart J 1995;129:527-35.

574. Thadani U, Chrysant S, Gorwit J, et al. Duration of effects of isradipine during twice daily therapy in angina pectoris. Cardiovasc Drugs Ther 1994;8:199-210.

575. Ekelund LG, Ulvenstam G, Walldius G, Aberg A. Effects of felodipine versus nifedipine on exercise tolerance in stable angina pectoris. Am J Cardiol 1994;73:658-60.

576. Pepine CJ, Feldman RL, Whittle J, Curry RC, Conti CR. Effect of diltiazem in patients with variant angina: a randomized doubleblind trial. Am Heart J 1981;101:719-25.

577. Antman E, Muller J, Goldberg S, et al. Nifedipine therapy for coronary-artery spasm. Experience in 127 patients. N Engl J Med 1980;302:1269-73.

578. Hill JA, Feldman RL, Pepine CJ, Conti CR. Randomized doubleblind comparison of nifedipine and isosorbide dinitrate in patients with coronary arterial spasm. Am J Cardiol 1982;49:431-8.

579. Johnson SM, Mauritson DR, Willerson JT, Cary JR, Hillis LD. Verapamil administration in variant angina pectoris. Efficacy shown by ECG monitoring. JAMA 1981;245:1849-51.

580. Chahine RA, Feldman RL, Giles TD, et al. Randomized placebocontrolled trial of amlodipine in vasospastic angina. Amlodipine Study 160 Group. J Am Coll Cardiol 1993;21:1365-70.

581. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-5.

582. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-31.

583. Opie LH, Messerli FH. Nifedipine and mortality. Grave defects in the dossier. Circulation 1995;92:1068-73.

584. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organization and the International Society of Hypertension. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J Hypertens 1997;15:105- 15.

585. Parmley WW, Nesto RW, Singh BN, Deanfield J, Gottlieb SO. Attenuation of the circadian patterns of myocardial ischemia with nifedipine GITS in patients with chronic stable angina. N-CAP Study Group. J Am Coll Cardiol 1992;19:1380-9.

586. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.

587. Thadani U, Zellner SR, Glasser S, et al. Double-blind, doseresponse, placebo-controlled multicenter study of nisoldipine: a new second-generation calcium channel blocker in angina pectoris. Circulation 1991;84:2398-408.

588. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and non-insulin dependent diabetes mellitus. Diabetes Care 1998;21:597-603.

589. Singh BN. Comparative efficacy and safety of bepridil and diltiazem in chronic stable angina pectoris refractory to diltiazem. The Bepridil Collaborative Study Group. Am J Cardiol 1991;68:306-12.

590. Bremner AD, Fell PJ, Hosie J, James IG, Saul PA, Taylor SH. Early side-effects of antihypertensive therapy: comparison of amlodipine and nifedipine retard. J Hum Hypertens 1993;7:79-81.

591. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990;82:1954-61.

592. Singh BN. Safety profile of bepridil determined from clinical trials in chronic stable angina in the United States. Am J Cardiol 1992;69:68D-74D.

593. Deanfield JE, Detry JM, Lichtlen PR, Magnani B, Sellier P, Thaulow E. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind Circadian Anti-Ischemia Program in Europe (CAPE Trial). J Am Coll Cardiol 1994;24:1460-7.

594. Lehmann G, Reiniger G, Beyerle A, Rudolph W. Pharmacokinetics and additional anti-ischaemic effectiveness of amlodipine, a once-daily calcium antagonist, during acute and long-term therapy of stable angina pectoris in patients pre-treated with a beta-blocker. Eur Heart J 1993;14:1531-5.

595. Glasser SP. Nisoldipine coat core as concomitant therapy in chronic stable angina pectoris. Am J Cardiol 1995;75:68E-70E.

596. Ronnevik PK, Silke B, Ostergaard O. Felodipine in addition to beta-adrenergic blockade for angina pectoris. a multicentre, randomized, placebo-controlled trial. Eur Heart J 1995;16:1535-41.

597. Abrams J. Nitroglycerin and long-acting nitrates in clinical practice. Am J Med 1983;74:85-94.

598. Kaski JC, Plaza LR, Meran DO, Araujo L, Chierchia S, Maseri A. Improved coronary supply: prevailing mechanism of action of nitrates in chronic stable angina. Am Heart J 1985;110:238-45.

599. Lacoste LL, Theroux P, Lidon RM, Colucci R, Lam JY. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. Ad Hoc Subcommittee of the Liaison Antithrombotic properties of transdermal nitroglycerin in stable angina pectoris. Am J Cardiol 1994;73:1058-62.

600. Tirlapur VG, Mir MA. Cardiorespiratory effects of isosorbide dinitrate and nifedipine in combination with nadolol: a doubleblind comparative study of beneficial and adverse antianginal drug interactions. Am J Cardiol 1984;53:487-92.

601. Schneider W, Maul FD, Bussmann WD, Lang E, Hor G, Kaltenbach M. Comparison of the antianginal efficacy of isosorbide dinitrate (ISDN) 40 mg and verapamil 120 mg three times daily in the acute trial and following two-week treatment. Eur Heart J 1988;9:149-58.

602. Ankier SI, Fay L, Warrington SJ, Woodings DF. A multicentre open comparison of isosorbide-5-mononitrate and nifedipine given prophylactically to general practice patients with chronic stable angina pectoris. J Int Med Res 1989;17:172-8.

603. Emanuelsson H, Ake H, Kristi M, Arina R. Effects of diltiazem and isosorbide-5-mononitrate, alone and in combination, on patients with stable angina pectoris. Eur J Clin Pharmacol 1989;36:561-5.

604. Akhras F, Chambers J, Jefferies S, Jackson G. A randomised double-blind crossover study of isosorbide mononitrate and nifedipine retard in chronic stable angina. Int J Cardiol 1989;24:191-6.

605. Akhras F, Jackson G. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. Lancet 1991;338:1036-9.

606. Abrams J. Glyceryl trinitrate (nitroglycerin) and the organic nitrates. Choosing the method of administration. Drugs 1987; 34:391-403.

607. Silber S. Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate. Eur J Clin Pharmacol 1990;38(Suppl 1):S35-51.

608. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol 1999;33:273-82.

609. Fung HL, Bauer JA. Mechanisms of nitrate tolerance. Cardiovasc Drugs Ther 1994;8:489-99.

610. Chirkov YY, Chirkova LP, Horowitz JD. Nitroglycerin tolerance at the platelet level in patients with angina pectoris. Am J Cardiol 1997;80:128-31.

611. Boesgaard S, Aldershvile J, Pedersen F, Pietersen A, Madsen JK, Grande P. Continuous oral N-acetylcysteine treatment and development of nitrate tolerance in patients with stable angina pectoris. J Cardiovasc Pharmacol 1991;17:889-93.

612. Balestrini AE, Menzio AC, Cabral R, et al. Penbutolol and molsidomine synergism in angina pectoris. A double blind ergometric trial. Eur J Clin Pharmacol 1984;27:1-5.

613. Meeter K, Kelder JC, Tijssen JG, et al. Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a longterm, double-blind, randomized study. J Cardiovasc Pharmacol 1992;20(Suppl 3):S59-66.

614. Guermonprez JL, Blin P, Peterlongo F. A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris. Eur Heart J 1993;14(Suppl B):30-4.

615. Hughes LO, Rose EL, Lahiri A, Raftery EB. Comparison of nicorandil and atenolol in stable angina pectoris. Am J Cardiol 1990;66:679-82.

616. Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol 1994;37:279-88.

617. Detry JM, Leclercq PJ. Trimetazidine European Multicenter Study versus propranolol in stable angina pectoris: contribution of Holter electrocardiographic ambulatory monitoring. Am J Cardiol 1995;76:8B-11B.

618. Cacciatore L, Cerio R, Ciarimboli M, et al. The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study. Drugs Exp Clin Res 1991;17:225-35.

619. Cocco G, Rousseau MF, Bouvy T, et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol 1992;20:131-8.

620. Upward JW, Akhras F, Jackson G. Oral labetalol in the management of stable angina pectoris in normotensive patients. Br Heart J 1985;53:53-7.

621. Crea F, Pupita G, Galassi AR, et al. Effects of theophylline, atenolol and their combination on myocardial ischemia in stable angina pectoris. Am J Cardiol 1990;66:1157-62.

622. Balakumaran K, Jovanovic A, Fels PW, et al. ST 567 (alinidine) in stable angina: a comparison with metoprolol. Eur Heart J 1987;8(Suppl L):153-7.

623. Frishman WH, Pepine CJ, Weiss RJ, Baiker WM. Addition of zatebradine, a direct sinus node inhibitor, provides no greater exercise tolerance benefit in patients with angina taking extendedrelease nifedipine: results of a multicenter, randomized, doubleblind, placebo-controlled, parallel-group study. The Zatebradine Study Group. J Am Coll Cardiol 1995;26:305-12.

624. Ikram H, Low CJ, Shirlaw TM, et al. Angiotensin converting enzyme inhibition in chronic stable angina: effects on myocardial ischaemia and comparison with nifedipine. Br Heart J 1994;71:30-3.

625. Klein WW, Khurmi NS, Eber B, Dusleag J. Effects of benazepril and metoprolol OROS alone and in combination on myocardial ischemia in patients with chronic stable angina. J Am Coll Cardiol 1990;16:948-56.

626. Cameron HA, Cameron CM, Ramsay LE. Comparison of single doses of ketanserin and placebo in chronic stable angina. Br J Clin Pharmacol 1986;22:114-6.

627. Feldman RL, Prida XE, Hill JA. Systemic and coronary hemodynamic effects of combined oral alpha- and beta-adrenergic blockade (labetalol) in normotensive patients with stable angina pectoris and positive exercise stress tests. Clin Cardiol 1988;11:383-8.

628. Raubach KH, Vlahov V, Wolter K, Bussmann WD. Double-blind randomized multicenter study on the efficacy of trapidil versus isosorbide dinitrate in stable angina pectoris. Clin Cardiol 1997;20:483-8.

629. Glasser SP, Singh SN, Humen DP. Safety and efficacy of monotherapy with fantofarone, a novel calcium channel antagonist, in patients with chronic stable angina pectoris. Fantofarone Study Group. J Clin Pharmacol 1997;37:53-7.

630. Lawson WE, Hui JC, Zheng ZS, et al. Can angiographic findings predict which coronary patients will benefit from enhanced external counterpulsation? Am J Cardiol 1996;77:1107-9.

631. Lawson WE, Hui JC, Zheng ZS, et al. Three-year sustained benefit from enhanced external counterpulsation in chronic angina pectoris. Am J Cardiol 1995;75:840-1.

632. Wang TJ, Stafford RS. National patterns and predictors of betablocker use in patients with coronary artery disease. Arch Intern Med 1998;158:1901-6.

633. Ardissino D, Savonitto S, Egstrup K, et al. Selection of medical treatment in stable angina pectoris: results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 1995;25:1516-21.

634. Arnman K, Ryden L. Comparison of metoprolol and verapamil in the treatment of angina pectoris. Am J Cardiol 1982;49:821-7.

635. Bjerle P, Olofsson, Glimvik O. Nicardipine and propranolol in angina pectoris: a comparative study with special reference to ergometer working capacity tests. Br J Clin Pharmacol 1986; 22:339S-43S.

636. Bowles MJ, Bala Subramanian V, Davies AB, Raftery EB. Double-blind randomized crossover trial of verapamil and propranolol in chronic stable angina. Am Heart J 1983;106:1297-306.

637. Crake T, Mulcahy D, Wright C, Fox K. Labetalol in the treatment of stable exertional angina pectoris: a comparison with nifedipine. Eur Heart J 1988;9:1200-5.

638. de Divitiis O, Liguori V, Di Somma S, et al. Bisoprolol in the treatment of angina pectoris: a double blind comparison with verapamil. Eur Heart J 1987;8(Suppl M):43-54.

639. Di Somma S, de Divitiis M, Bertocchi F, et al. Treatment of hypertension associated with stable angina pectoris: favourable interaction between new metoprolol formulation (OROS) and nifedipine. Cardiologia 1996;41:635-43.

640. Findlay IN, Dargie HJ. The effects of nifedipine, atenolol and that combination on left ventricular function. Postgrad Med J 1983;59(Suppl 2):70-3.

641. Findlay IN, MacLeod K, Ford M, Gillen G, Elliott AT, Dargie HJ. Treatment of angina pectoris with nifedipine and atenolol: efficacy and effect on cardiac function. Br Heart J 1986;55:240-5.

.642. Findlay IN, MacLeod K, Gillen G, Elliott AT, Aitchison T, Dargie HJ. A double blind placebo controlled comparison of verapamil, atenolol, and their combination in patients with chronic stable angina pectoris. Br Heart J 1987;57:336-43.

643. Frishman WH, Klein NA, Klein P, et al. Comparison of oral propranolol and verapamil for combined systemic hypertension and angina pectoris: a placebo-controlled double-blind randomized crossover trial. Am J Cardiol 1982;50:1164-72.

644. Frishman WH. Comparative efficacy and concomitant use of bepridil and beta blockers in the management of angina pectoris. Am J Cardiol 1992;69:50D-55D.

645. Higginbotham MB, Morris KG, Coleman RE, Cobb FR. Chronic stable angina monotherapy. Nifedipine versus propranolol. Am J Med 1989;86:1-5.

646. Humen DP, Kostuk WJ. Clinical response and effects on left ventricular function of isosorbide dinitrate added to propranolol or diltiazem monotherapy in patients with chronic stable angina. Can J Cardiol 1991;7:74-80.

647. Johnson SM, Mauritson DR, Corbett JR,Woodward W,Willerson JT, Hillis LD. Double-blind, randomized, placebo-controlled comparison of propranolol and verapamil in the treatment of patients with stable angina pectoris. Am J Med 1981;71:443-51.

648. Kenny J, Kiff P, Holmes J, Jewitt DE. Beneficial effects of diltiazem and propranolol, alone and in combination, in patients with stable angina pectoris. Br Heart J 1985;53:43-6.

649. Livesley B, Catley PF, Campbell RC, Oram S. Double-blind evaluation of verapamil, propranolol, and isosorbide dinitrate against a placebo in the treatment of angina pectoris. Br Med J 1973;1:375-8.

650. Lynch P, Dargie H, Krikler S, Krikler D. Objective assessment of antianginal treatment: a double-blind comparison of propranolol, nifedipine, and their combination. Br Med J 1980;281:184-7.

651. McGill D, McKenzie W, McCredie M. Comparison of nicardipine and propranolol for chronic stable angina pectoris. Am J Cardiol 1986;57:39-43.

652. Nadazdin A, Davies GJ. Investigation of therapeutic mechanisms of atenolol and diltiazem in patients with variable-threshold angina. Am Heart J 1994;127:312-7.

653. Pflugfelder PW, Humen DP, O’Brien PA, Purves PD, Jablonsky G, Kostuk WJ. Comparison of bepridil with nadolol for angina pectoris. Am J Cardiol 1987;59:1283-8.

654. Rae AP, Beattie JM, Lawrie TD, Hutton I. Comparative clinical efficacy of bepridil, propranolol and placebo in patients with chronic stable angina. Br J Clin Pharmacol 1985;19:343-52.

655. Southall E, Nutt NR, Thomas RD. Chronic stable angina: comparison of verapamil and propranolol. J Int Med Res 1982;10:361-6.

656. van der Does R, Eberhardt R, Derr I, Ehmer B. Efficacy and safety of carvedilol in comparison with nifedipine sustained-release in chronic stable angina. J Cardiovasc Pharmacol 1992;19(Suppl 1):S122-7.

657. van Dijk RB, Lie KI, Crijns HJ. Diltiazem in comparison with metoprolol in stable angina pectoris. Eur Heart J 1988;9:1194-9.

658. Wheatley D. A comparison of diltiazem and atenolol in angina. Postgrad Med J 1985;61:785-9.

659. Ahuja RC, Sinha N, Kumar RR, Saran RK. Effect of metoprolol and diltiazem on the total ischaemic burden in patients with chronic stable angina: a randomized controlled trial. Int J Cardiol 1993;41:191-9.

660. Egstrup K, Andersen PE Jr. Transient myocardial ischemia during nifedipine therapy in stable angina pectoris, and its relation to coronary collateral flow and comparison with metoprolol. Am J Cardiol 1993;71:177-83.

661. Hung J, Lamb IH, Connolly SJ, Jutzy KR, Goris ML, Schroeder JS. The effect of diltiazem and propranolol, alone and in combination, on exercise performance and left ventricular function in patients with stable effort angina: a double-blind, randomized, and placebo-controlled study. Circulation 1983;68:560-7.

662. Lai C, Onnis E, Orani E, et al. Felodipine improves the antiischaemic effect of metoprolol in stable effort-induced angina. Drug Invest 1992;4:30-3.

663. Parker JO, Farrell B. Comparative antianginal effects of bepridil and propranolol in angina pectoris. Am J Cardiol 1986;58:449-52.

664. Sadick NN, Tan AT, Fletcher PJ, Morris J, Kelly DT. A doubleblind randomized trial of propranolol and verapamil in the treatment of effort angina. Circulation 1982;66:574-9.

665. Subramanian VB, Bowles MJ, Davies AB, Raftery EB. Calcium channel blockade as primary therapy for stable angina pectoris. A double-blind placebo-controlled comparison of verapamil and propranolol. Am J Cardiol 1982;50:1158-63.

666. Missed opportunities in preventive counseling for cardiovascular disease-United States, 1995. MMWR Morb Mortal Wkly Rep 1998;47:91-5.

667. Plach S, Wierenga ME, Heidrich SM. Effect of a postdischarge education class on coronary artery disease knowledge and selfreported health-promoting behaviors. Heart Lung 1996;25:367-72.

668. O’Neill C, Normand C, Cupples M, McKnight A. Cost effectiveness of personal health education in primary care for people with angina in the greater Belfast area of Northern Ireland. J Epidemiol Community Health 1996;50:538-40.

669. Larson CO, Nelson EC, Gustafson D, Batalden PB. The relationship between meeting patients’ information needs and their satisfaction with hospital care and general health status outcomes. Int J Qual Health Care 1996;8:447-56.

670. Lewis BS, Lynch WD. The effect of physician advice on exercise behavior. Prev Med 1993;22:110-21.

671. Ockene JK, Kristeller J, Pbert L, et al. The physician-delivered smoking intervention project: can short-term interventions produce long-term effects for a general outpatient population? Health Psychol 1994;13:278-81.

672. Liao L, Jollis JG, DeLong ER, Peterson ED, Morris KG, Mark DB. Impact of an interactive video on decision making of patients with ischemic heart disease. J Gen Intern Med 1996;11:373-6.

673. Hill J. A practical guide to patient education and information giving. Baillieres Clin Rheumatol 1997;11:109-27.

674. Kingsbury K. Taking AIM: how to teach primary and secondary prevention effectively. Can J Cardiol 1998;14(Suppl A):22A-26A.

675. Winslow E, Bohannon N, Brunton SA, Mayhew HE. Lifestyle modification: weight control, exercise, and smoking cessation. Am J Med 1996;101:25S-31S.

676. The multiple risk factor intervention trial (MRFIT). A national study of primary prevention of coronary heart disease. JAMA 1976;235:825-7.

677. Moore SM. Effects of interventions to promote recovery in coronary artery bypass surgical patients. J Cardiovasc Nurs 1997;12:59-70.

678. Oldridge NB, Guyatt GH, Fischer ME, Rimm AA. Cardiac rehabilitation after myocardial infarction: combined experience of randomized clinical trials. JAMA 1988;260:945-50.

679. Duryee R. The efficacy of inpatient education after myocardial infarction. Heart Lung 1992;21:217-25.

680. Wang WW. The educational needs of myocardial infarction patients. Prog Cardiovasc Nurs 1994;9:28-36.

681. Chan V. Content areas for cardiac teaching: patients’ perceptions of the importance of teaching content after myocardial infarction. J Adv Nurs 1990;15:1139-45.

682. Rhodes KS, Bookstein LC, Aaronson LS, Mercer NM, Orringer CE. Intensive nutrition counseling enhances outcomes of National Cholesterol Education Program dietary therapy. J Am Diet Assoc 1996;96:1003-10.

683. Czar ML, Engler MM. Perceived learning needs of patients with coronary artery disease using a questionnaire assessment tool. Heart Lung 1997;26:109-17.

684. Albarran JW, Bridger S. Problems with providing education on resuming sexual activity after myocardial infarction: developing written information for patients. Intensive Crit Care Nurs 1997;13:2-11.

685. Dracup K, Alonzo AA, Atkins JM, et al. The physician’s role in minimizing prehospital delay in patients at high risk for acute myocardial infarction: recommendations from the National Heart Attack Alert Program. Working Group on Educational Strategies to Prevent Prehospital Delay in Patients at High Risk for Acute Myocardial Infarction. Ann Intern Med 1997;126:645-51.

686. Gaspoz JM, Unger PF, Urban P, et al. Impact of a public campaign on pre-hospital delay in patients reporting chest pain. Heart 1996;76:150-5.

687. AHA Home Page. Available at: http://www.americanheart.org/Heart_and_ Stroke_A_Z_Guide/cvds.html.

688. Dracup K, Moser DK, Guzy PM, Taylor SE, Marsden C. Is cardiopulmonary resuscitation training deleterious for family members of cardiac patients? Am J Public Health 1994;84:116-8.

689. Pasternak RC, Grundy SM, Levy D, Thompson SD. Task Force III: spectrum of risk factors for coronary heart disease. J Am Coll Cardiol 1996;27:978-90.

690. McBride PE. The health consequences of smoking. Cardiovascular diseases. Med Clin North Am 1992;76:333-53.

691. Government Printing Office. Reducing the Health Consequences of Smoking: 25 Years of Progress. Washington DC: Government Printing Office, 1989.

692. Doll R, Peto R. Mortality in relation to smoking: 20 years’ observations on male British doctors. Br Med J 1976;2:1525-36.

693. Willett WC, Green A, Stampfer MJ, et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 1990;322:213-7.

694. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 1994;110:121-61.

695. The health benefits of smoking cessation. A report of the Surgeon General. Washington, DC: US Department of Health and Human Services, 1990.

696. Rose GA, Hamilton PJS, Colwell L, Shipley MJ. A randomized controlled trial of antismoking advice: 10 year results. J Epidemiol Community Health 1982;36:102-8.

697. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results. JAMA 1982;248:1465-77.

698. Hjermann I, Velve Byre K, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men. Lancet 1981;2:1303-10.

699. Kannel WB, D’Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1986;113:1006-10.

700. Davis JW, Hartman CR, Lewis HD Jr, et al. Cigarette smoking induced enhancement of platelet function: lack of prevention by aspirin in men with coronary artery disease. J Lab Clin Med 1985;105:479-83.

701. Taylor AE, Johnson DC, Kazemi H. Environmental tobacco smoke and cardiovascular disease. A position paper from the Council on Cardiopulmonary and Critical Care, American Heart Association. Circulation 1992;86:699-702.

702. Winniford MD, Jansen DE, Reynolds GA, et al. Cigarette smoking-induced coronary vasoconstriction in atherosclerotic coronary artery disease and prevention by calcium antagonists and nitroglycerin. Am J Cardiol 1987;59:203-7.

703. Taylor CB, Houston-Miller N, Killen JD, et al. Smoking cessation after acute myocardial infarction: effects of a nurse-managed intervention. Ann Intern Med 1990;113:118-23.

704. Singh RB, Rastogi SS, Verma R, et al. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. BMJ 1992;304:1015-9.

705. Schuler G, Hambrecht R, Schlierf G, et al. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation 1992;86:1-11.

706. Superko HR, Krauss RM. Coronary artery disease regression: convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994;90:1056-69.

707. Rossouw JE. Lipid-lowering interventions in angiographic trials. Am J Cardiol 1995;76:86C-92C.

708. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153:154-83.

709. Stamler J, Neaton J, Wentworth D. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension 1993;13:2-12.

710. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74.

711. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967;202:1028-34.

712. Effects of treatment on morbidity in hypertension, II: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970;213:1143-52.

713. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.

714. Cutler JA, Psaty BM, McMahon S, Furberg CD. Public health issues in hypertension control: what has been learned from clinical trials. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed. New York: Raven Press, 1995:253-70.

715. Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE. Adjunctive drug therapy of acute myocardial infarction-evidence from clinical trials. N Engl J Med 1996;335:1660-7.

716. Smith SC Jr, Blair SN, Criqui MH, et al. AHA consensus panel statement: preventing heart attack and death in patients with coronary disease. The Secondary Prevention Panel. J Am Coll Cardiol 1995;26:292-4.

717. Alderman MH, Cohen H, Roque R, Madhavan S. Effect of longacting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 1997;349:594-8.

718. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996;27:1214-8.

719. Gibson RS, Boden WE. Calcium channel antagonists: friend or foe in postinfarction patients? Am J Hypertens 1996;9:172S-6S.

720. Kannel WB. Coronary risk factors: an overview. In:Willerson JT, Cohn JN, eds. Cardiovascular Medicine. New York: Churchill Livingstone, 1995:1809-92.

721. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988;108:7-13.

722. Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study. Ann Intern Med 1970;72:813-22.

723. Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Ann Intern Med 1969;71:89-105.

724. Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986;105:173-8.

725. Liao Y, Cooper RS, McGee DL, Mensah GA, Ghali JK. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995;273:1592-7.

726. Bikkina M, Levy D, Evans JC, et al. Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study. JAMA 1994;272:33-6.

727. Ghali JK, Liao Y, Simmons B, Castaner A, Cao G, Cooper RS. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 1992;117:831-6.

728. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.

729. Neaton JD, Grimm RH, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993;270:713-24.

730. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106.

731. Ridker PM. An epidemiologic assessment of thrombotic risk factors for cardiovascular disease. Curr Opin Lipidol 1992;3:285-90.

732. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.

733. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993;118:956-63.

734. Kannel WB, D’Agostino RB, Belanger AJ. Update on fibrinogen as a cardiovascular risk factor. Ann Epidemiol 1992;2:457-66.

735. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635-41.

736. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994;14:54-9.

737. Trip MD, Manger Cats V, Van Capelle FJL, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990;322:1549-54.

738. Elwood PC, Renaud S, Sharp DS, Beswick AD, O’Brien JR, Yarnell JWG. Ischemic heart disease and platelet aggregation: The Caerphilly Collaborative Heart Disease Study. Circulation 1991;83:38-44.

739. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991;66:351-5.

740. American Diabetes Association. Clinical practice recommendations 1998: screening for type 2 diabetes. Diabetes Care 1998;21(Suppl 1):1-98.

741. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.

742. Getz GS. Report on the workshop on diabetes and mechanisms of atherogenesis. September 17th and 18th, 1992, Bethesda, Maryland. Arterioscler Thromb 1993;13:459-64.

743. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Cayatte AJ, Rozek MM. Pathogenesis of the atherosclerotic lesion. Implications for diabetes mellitus. Circulation 1992;15:1156-67.

744. Stamler J. Epidemiology, established major risk factors, and the primary prevention of coronary heart disease. In: Parmley WW, Chatterjee K, eds. Cardiology. Philadelphia: JB Lippincott; 1987:1-41.

745. Butler WJ, Ostrander LD, Carman WJ, Lamphiear DE. Mortality from coronary heart disease in the Tecumseh study: long-term effect of diabetes mellitus, glucose tolerance and other risk factors. Am J Epidemiol 1985;121:541-7.

746. Alderman EL, Corley SD, Fisher LD, et al. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). CASS Participating Investigators and Staff. J Am Coll Cardiol 1993;22:1141-54.

747. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329:304-9.

748. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.

749. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.

750. Connaughton M, Weber J. Diabetes in coronary artery disease: time to stop taking the tablets. Heart 1998;80:108-9.

751. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.

752. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-20.

753. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15.

754. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-23. Reference deleted during update.

755. Manson JE, Gaziano JM, Jonas MA, Hennekens CH. Antioxidants and cardiovascular disease: a review. J Am Coll Nutr 1993;12:426-32.

756. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-77.

757. Fletcher GF, Balady G, Blair SN, et al. Statement on exercise: benefits and recommendations for physical activity programs for all Americans. A statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association. Circulation 1996;94:857-62.

758. Froelicher V, Jensen D, Genter F, et al. A randomized trial of exercise training in patients with coronary heart disease. JAMA 1984;252:1291-7.

759. Sebrechts CP, Klein JL, Ahnve S, Froelicher VF, Ashburn WL. Myocardial perfusion changes following 1 year of exercise training assessed by thallium-201 circumferential count profiles. Am Heart J 1986;112:1217-26.

760. Oldridge NB, McCartney N, Hicks A, Jones NL. Maximal isokinetic cycle ergometry in patients with coronary artery disease. Improvement in maximal isokinetic cycle ergometry with cardiac rehabilitation. Med Sci Sports Exerc 1989;21:308-12.

761. Hambrecht R, Niebauer J, Marburger C, et al. Various intensities of leisure time physical activity in patients with coronary artery disease: effects on cardiorespiratory fitness and progression of coronary atherosclerotic lesions. J Am Coll Cardiol 1993;22:468-77.

762. Fletcher BJ, Dunbar SB, Felner JM, et al. Exercise testing and training in physically disabled men with clinical evidence of coronary artery disease. Am J Cardiol 1994;73:170-4.

763. Ornish D, Scherwitz LW, Doody RS, et al. Effects of stress management training and dietary changes in treating ischemic heart disease. JAMA 1983;249:54-9.

764. May GA, Nagle FJ. Changes in rate-pressure product with physical training of individuals with coronary artery disease. Phys Ther 1984;64:1361-6.

765. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994;89:975-90.

766. Cannistra LB, Balady GJ, O’Malley CJ, Weiner DA, Ryan TJ. Comparison of the clinical profile and outcome of women and men in cardiac rehabilitation. Am J Cardiol 1992;69:1274-9.

767. O’Callaghan WG, Teo KK, O’Riordan J, Webb H, Dolphin T, Horgan JH. Comparative response of male and female patients with coronary artery disease to exercise rehabilitation. Eur Heart J 1984;5:649-51.

768. Oldridge NB, LaSalle D, Jones NL. Exercise rehabilitation of female patients with coronary heart disease. Am Heart J 1980;100:755-7.

769. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990;336:129-33.

770. Todd IC, Ballantyne D. Effects of exercise training on the total ischaemic burden: an assessment by 24 hour ambulatory electrocardiographic monitoring. Br Heart J 1992;68:560-6.

771. Denollet J. Emotional distress and fatigue in coronary heart disease: the Global Mood Scale (GMS). Psychol Med 1993;23:111-21.

772. Oberman A, Cleary P, Larosa JC, Hellerstein HK, Naughton J. Changes in risk factors among participants in a long-term exercise rehabilitation program. Adv Cardiol 1982;31:168-75.

773. Nikolaus T, Schlierf G, Vogel G, Schuler G, Wagner I. Treatment of coronary heart disease with diet and exercise-problems of compliance. Ann Nutr Metab 1991;35:1-7.

774. Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas’ Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-9.

775. Lee AP, Ice R, Blessey R, Sanmarco ME. Long-term effects of physical training on coronary patients with impaired ventricular function. Circulation 1979;60:1519-26.

776. Kennedy CC, Spiekerman RE, Lindsay MI, Mankin HT, Frye RL, McCallister BD. One-year graduated exercise program for men with angina pectoris: evaluation by physiologic studies and coronary arteriography. Mayo Clin Proc 1976;51:231-6.

777. Letac B, Cribier A, Desplanches JF. A study of left ventricular function in coronary patients before and after physical training. Circulation 1977;56:375-8.

778. Hung J, Gordon EP, Houston N, Haskell WL, Goris ML, DeBusk RF. Changes in rest and exercise myocardial perfusion and left ventricular function 3 to 26 weeks after clinically uncomplicated acute myocardial infarction: effects of exercise training. Am J Cardiol 1984;54:943-50.

779. Giannuzzi P, Tavazzi L, Temporelli PL, et al. Long-term physical training and left ventricular remodeling after anterior myocardial infarction: results of the Exercise in Anterior Myocardial Infarction (EAMI) trial. EAMI Study Group. J Am Coll Cardiol 1993;22:1821-9.

780. Grodzinski E, Jette M, Blumchen G, Borer JS. Effects of a fourweek training program on left ventricular function as assessed by radionuclide ventriculography. J Cardiopulm Rehabil 1987;7:518-24.

781. Sullivan MJ, Higginbotham MB, Cobb FR. Exercise training in patients with severe left ventricular dysfunction: hemodynamic and metabolic effects. Circulation 1988;78:506-15.

782. Jugdutt BI, Michorowski BL, Kappagoda CT. Exercise training after anterior Q wave myocardial infarction: importance of regional left ventricular function and topography. J Am Coll Cardiol 1988;12:362-72.

783. Hertzeanu HL, Shemesh J, Aron LA, et al. Ventricular arrhythmias in rehabilitated and nonrehabilitated post-myocardial infarction patients with left ventricular dysfunction. Am J Cardiol 1993;71:24-7.

784. Haskell WL, Van Camp SP, Peterson RA. Cardiovascular complications of outpatient cardiac rehabilitation programs. JAMA 1986;256:1160-3.

785. O’Connor GT, Buring JE,Yusuf S, et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989;80:234-44.

786. Plavsic C, Turkulin K, Perman Z, et al. The results of exercise therapy in coronary prone individuals and coronary patients. G Ital Cardiol 1976;6:422-32.

787. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med 1989;321:641-6.

788. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial [published erratum appears in JAMA 1995 Dec 6;274:1676]. JAMA 1995;273:199-208.

789. Manolio TA, Furberg CD, Shemanski L, et al. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. The CHS Collaborative Research Group. Circulation 1993;88:2163-71.

790. Hong MK, Romm PA, Reagan K, Green CE, Rackley CE. Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women. Am J Cardiol 1992;69:176-8.

791. Nabulsi AA, Folsom AR, White A, et al. Association of hormonereplacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 1993;328:1069-75.

792. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.

793. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses’ Health Study. N Engl J Med 1991;325:756-62.

794. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.

795. Sullivan JM, Vander Zwaag R, Lemp GF, et al. Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med 1988;108:358-63.

796. Gruchow HW, Anderson AJ, Barboriak JJ, Sobocinski KA. Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J 1988;115:954-63.

797. Sullivan JM, Vander Zwaag R, Hughes JP, et al. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med 1990;150:2557-62.

798. Sullivan JM, El-Zeky F,Vander Zwaag R, Ramanathan KB. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am J Cardiol 1997;79:847-50.

799. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.

800. Friedman M, Rosenman RH. Association of specific overt behavior patterns with blood and cardiovascular findings: blood cholesterol level, blood clotting time, incidence of arcus senilis and clinical coronary artery disease. JAMA 1959;169:1286-97.

801. Rosenman RH, Brand RJ, Sholtz RI, Friedman M. Multivariate prediction of coronary heart disease during 8.5 year follow-up in the Western Collaborative Group Study. Am J Cardiol 1976;37:903-10.

802. Rosenman RH, Brand RJ, Jenkins D, Friedman M, Straus R, Wurm M. Coronary heart disease in Western Collaborative Group Study. Final follow-up experience of 8+ years. JAMA 1975;233:872-7.

803. Case RB, Heller SS, Case NB, Moss AJ. Type A behavior and survival after acute myocardial infarction. N Engl J Med 1985;312:737-41.

804. Shekelle RB, Gale M, Norusis M. Type A score (Jenkins Activity Survey) and risk of recurrent coronary heart disease in the Aspirin Myocardial Infarction Study. Am J Cardiol 1985;56:221-5.

805. Shekelle RB, Hulley SB, Neaton JD, et al. The MRFIT behavior pattern study, II. Type A behavior and incidence of coronary heart disease. Am J Epidemiol 1985;122:559-70.

806. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA 1993;270:1819-25.

807. Williams RB. Neurobiology, cellular and molecular biology, and psychosomatic medicine. Psychosom Med 1994;56:308-15.

808. Barefoot JC, Dahlstrom WG, Williams RB Jr. Hostility, CHD incidence, and total mortality: a 25-year follow-up study of 255 physicians. Psychosom Med 1983;45:59-63.

809. Shekelle RB, Gale M, Ostfeld AM, Paul O. Hostility, risk of coronary heart disease, and mortality. Psychosom Med 1983;45:109-14.

810. Frasure-Smith N, Prince R. The ischemic heart disease life stress. Monetary program: impact on mortality. Psychosom Med 1985;47:431-45.

811. Friedman M, Thoresen CE, Gill JJ, et al. Alteration of type A behavior and reduction in cardiac recurrences in postmyocardial infarction patients. Am Heart J 1984;108:237-48.

812. Nunes EV, Frank KA, Kornfeld DS. Psychologic treatment for the type A behavior pattern and for coronary heart disease: a metaanalysis of the literature. Psychosom Med 1987;49:159-73.

813. Bohachick P. Progressive relaxation training in cardiac rehabilitation: effect on psychologic variables. Nurs Res 1984;33:283-7.

814. Blumenthal JA, Jiang W, Babyak MA, et al. Stress management and exercise training in cardiac patients with myocardial ischemia: effects on prognosis and evaluation of mechanisms. Arch Intern Med 1997;157:2213-23.

815. Carney RM, Rich MW, Tevelde A, Saini J, Clark K, Jaffe AS. Major depressive disorder in coronary artery disease. Am J Cardiol 1987;60:1273-5.

816. Schleifer SJ, Macari-Hinson MM, Coyle DA, et al. The nature and course of depression following myocardial infarction. Arch Intern Med 1989;149:1785-9.

817. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study [published erratum appears in Circulation 1998 May 19;97:1995]. Circulation 1998;97:1029-36.

818. Reaven GM. Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia, and coronary heart disease. Am Heart J 1991;121:1283-8.

819. Grundy SM, Vega GL. Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Implications for treatment. Arch Intern Med 1992;152:28-34.

820. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primaryprevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.

821. NIH Consensus Development Panel on Triglyceride H-DL and Coronary Heart Disease. Triglyceride, high-density lipoprotein, and coronary heart disease. JAMA 1993;269:505-10.

822. Scanu AM, Lawn RM, Berg K. Lipoprotein(a) and atherosclerosis. Ann Intern Med 1991;115:209-18.

823. Kostner GM, Krempler F. Lipoprotein(a). Curr Opin Lipidol 1992;3:279-84.

824. Genest JJ, Jenner JL, McNamara JR, et al. Prevalence of lipoprotein (a) [Lp(a)] excess in coronary artery disease. Am J Cardiol 1991;67:1039-145.

825. Genest J Jr, Malinow MR. Homocysteine and coronary artery dis ease. Curr Opin Lipidol 1992;3:295-9. 826. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.

827. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-81.

828. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotidartery stenosis. N Engl J Med 1995;332:286-91.

829. Selhub J, Jacques PF,Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-8.

830. Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993;57:47-53.

831. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995;91:2488-96.

832. Jialal I, Scaccini C. Antioxidants and atherosclerosis. Curr Opin Lipidol 1992;3:324-8.

833. Nyyssonen K, Parviainen MT, Salonen R, Tuomilehto J, Salonen JT. Vitamin C deficiency and risk of myocardial infarction: prospective population study of men from eastern Finland. BMJ 1997;314:634-8.

834. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-35.

835. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxident Study. Lancet 1996;347:781-6.

836. Rodes J, Cote G, Lesperance J, et al. Prevention of restenosis after angioplasty in small coronary arteries with probucol. Circulation 1998;97:429-36.

837. Regnstrom J, Walldius G, Nilsson S, et al. The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis. Atherosclerosis 1996;125:217-29.

838. Gaziano JM, Buring JE, Breslow JL, et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med 1993;329:1829-34.

839. Stampfer MJ, Colditz GA, Willett WC, Speizer FE, Hennekens CH. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Med 1988;319:267-73.

840. Yano K, Rhoads G, Kagan A. Coffee, alcohol and risk of coronary heart disease among Japanese men living in Hawaii. N Engl J Med 1977;297:405-9.

841. Hertog MG,Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993;342:1007-11.

842. Rimm EB, Katan MB, Ascherio A, Stampfer MJ, Willett WC. Relation between intake of flavonoids and risk for coronary heart disease in male health professionals. Ann Intern Med 1996;125:384-9.

843. Hopkins PN, Williams RR. A survey of 246 suggested coronary risk factors. Atherosclerosis 1981;40:1-52.

844. Ball KP, Hanington E, McAllen PM, et al. Low fat diet in myocardial infarction. Lancet 1965;2:501-4.

845. Rose GA, Thompson WB, Williams RT. Corn oil in treatment of ischemic heart disease. BMJ 1965;1:1531-3.

846. Woodhill JM, Palmer AJ, Leelerthaepin B, McGilchrist C, Blacket RB. Low fat, low cholesterol diet in secondary prevention of coronary heart disease. Adv Exp Med Biol 1978;109:317-30.

847. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet And Reinfarction Trial (DART). Lancet 1989;2:757-61.

848. Leren P. The Oslo diet-heart study. Eleven-year report. Circulation 1970;42:935-42.

849. Lorgeril M, Mamelle N, Salen P, et al. Mediterranean alphalinolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994;343:1454-9.

850. Israel DH, Gorlin R. Fish oils in prevention of atherosclerosis. J Am Coll Cardiol 1992;19:174-85.

851. O’Connor GT, Malenka DJ, Olmstead ME, Johnson PS, Hennekens CH. A meta-analysis of randomized trials of fish oils in the prevention of restenosis following coronary angioplasty. Am J Prev Med 1992;8:186-92.

852. Gapinski JP, Van Ruiswyk JV, Heudebart GR, Schectman GS. Preventing restenosis with fish oils following coronary angioplasty: a meta-analysis. Arch Intern Med 1993;153:1595-601.

853. Warshafsky S, Kamer RS, Sivak SL. Effect of garlic on total serum cholesterol: a meta-analysis. Ann Intern Med 1993;119:599-605.

854. Silagy CA, Neil HA. A meta-analysis of the effect of garlic on blood pressure. J Hypertens 1994;12:463-8.

855. Berthold HK, Sudhop T, von Bergmann K. Effect of a garlic oil preparation on serum lipoproteins and cholesterol metabolism: a randomized controlled trial. JAMA 1998;279:1900-2.

856. Isaacsohn JL, Moser M, Stein EA, et al. Garlic powder and plasma lipids and lipoproteins: a multicenter, randomized, placebocontrolled trial. Arch Intern Med 1998;158:1189-94.

857. Jain AK, Vargas R, Gotzkowsky S, McMahon FG. Can garlic reduce levels of serum lipids? A controlled clinical study. Am J Med 1993;94:632-5.

858. Ernst E. Chelation therapy for peripheral arterial occlusive disease: a systematic review. Circulation 1997;96:1031-3.

859. Lytle BW, Loop FD, Cosgrove DM, Ratliff NB, Easley K, Taylor PC. Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts. J Thorac Cardiovasc Surg 1985;89:248-58.

860. Bourassa MG, Campeau L, Lesperance J. Changes in grafts and in coronary arteries after coronary bypass surgery. Cardiovasc Clin 1991;21:83-100.

861. FitzGibbon GM, Leach AJ, Kafka HP, Keon WJ. Coronary bypass graft fate: long-term angiographic study. J Am Coll Cardiol 1991;17:1075-80.

862. Chesebro JH, Fuster V, Elveback LR, et al. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med 1984;310:209-14.

863. Gavaghan TP, Gebski V, Baron DW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. Circulation 1991;83:1526-33.

864. Goldman S, Copeland J, Moritz T, et al. Starting aspirin therapy after operation. Effects on early graft patency. Department of Veterans Affairs Cooperative Study Group. Circulation 1991;84:520-6.

865. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-62.

866. Loop FD, Lytle BW, Cosgrove DM, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med 1986;314:1-6.

867. Lytle BW, Cosgrove DM III. Coronary artery bypass surgery. Curr Probl Surg 1992;29:733-807.

868. Cameron A, Davis KB, Green G, Schaff HV. Coronary bypass surgery with internal-thoracic-artery grafts-effects on survival over a 15-year period. N Engl J Med 1996;334:216-9.

869. The VA Coronary Artery Bypass Surgery Cooperative Study Group. Eighteen-year follow-up in the Veterans Affairs Cooperative Study of Coronary Artery Bypass Surgery for stable angina. Circulation 1992;86:121-30.

870. Varnauskas E. Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. N Engl J Med 1988;319:332-7.

871. Passamani E, Davis KB, Gillespie MJ, Killip T. A randomized trial of coronary artery bypass surgery. Survival of patients with a low ejection fraction. N Engl J Med 1985;312:1665-71.

872. Myers WO, Schaff HV, Gersh BJ, et al. Improved survival of surgically treated patients with triple vessel coronary artery disease and severe angina pectoris. A report from the Coronary Artery Surgery Study (CASS) registry. J Thorac Cardiovasc Surg 1989;97:487-95.

873. Rogers WJ, Coggin CJ, Gersh BJ, et al. Ten-year follow-up of quality of life in patients randomized to receive medical therapy or coronary artery bypass graft surgery. The Coronary Artery Surgery Study (CASS). Circulation 1990;82:1647-58.

874. Califf RM, Harrell FE Jr, Lee KL, et al. The evolution of medical and surgical therapy for coronary artery disease: a 15-year perspective. JAMA 1989;261:2077-86.

875. Topol EJ, Leya F, Pinkerton CA, et al. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group. N Engl J Med 1993;329:221-7.

876. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.

877. Adelman AG, Cohen EA, Kimball BP, et al. A comparison of directional atherectomy with balloon angioplasty for lesions of the left anterior descending coronary artery. N Engl J Med 1993;329:228-33.

878. Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. N Engl J Med 1992;326:10-6.

879. RITA-2 Trial Participants. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. Lancet 1997;350:461-8.

880. Davies RF, Goldberg AD, Forman S, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 1997;95:2037-43.

881. Sharaf BL, Williams DO, Miele NJ, et al. A detailed angiographic analysis of patients with ambulatory electrocardiographic ischemia: results from the Asymptomatic Cardiac Ischemia Pilot (ACIP) Study Angiographic Core Laboratory. J Am Coll Cardiol 1997;29:78-84.

882. Hueb WA, Bellotti G, de Oliveira SA, et al. The Medicine, Angioplasty or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. J Am Coll Cardiol 1995;26:1600-5.

883. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease [published erratum appears in N Engl J Med 1997;336:147]. N Engl J Med 1996;335:217-25.

884. King SBI, Lembo NJ, Weintraub WS, et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). N Engl J Med 1994;331:1044-50.

885. Moliterno DJ, Elliott JM. Randomized trials of myocardial revascularization. Curr Probl Cardiol 1995;20:125-90.

886. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1997;96:1761-9.

887. O’Rourke RA. Role of myocardial revascularization in sudden cardiac death. Circulation 1992;85:I-112-I-117.

888. Holmes DR Jr, Davis K, Gersh BJ, Mock M, Pettinger MB. Risk factor profiles of patients with sudden cardiac death and death from other cardiac causes. A report from the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol 1989;13:524-31.

889. Tresch DD,Wetherbee JN, Siegel R, et al. Long-term follow-up of survivors of prehospital sudden cardiac death treated with coronary bypass surgery. Am Heart J 1985;110:1139-45.

890. King SBI, Barnhart HX, Kosinski AS, et al. Angioplasty or surgery for multivessel coronary artery disease: comparison of eligible registry and randomized patients in the EAST trial and influence of treatment selection on outcomes. Emory Angioplasty versus Surgery Trial Investigators. Am J Cardiol 1997;79:1453-9.

891. Mahmarian JJ, Moye LA, Verani MS, Bloom MF, Pratt CM. High reproducibility of myocardial perfusion defects in patients undergoing serial exercise thallium-201 tomography. Am J Cardiol 1995;75:1116-9.

892. Ryan TJ, Antman EM, Brooks NH, et al. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction. 1999. American College of Cardiology Web site. Available at: http://www.acc.org/clinical/guidelines/nov96/1999/index.htm. Accessed October 17, 2002.

893. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of the Patients with Unstable Angina). 2002. American College of Cardiology Web site. Available at: http://www.acc.org/clinical/guidelines/unstable/incorporated/index.htm. Accessed October 17, 2002.

894. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). 2002. American College of Cardiology Web site. Available at: http://www.acc.org/clinical/guidelines/exercise/exercise_clean.pdf. Accessed October 17, 2002.

895. O’Rourke RA, Brundage BH, Froelicher VF, et al. American College of Cardiology/American Heart Association Expert Consensus Document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. J Am Coll Cardiol 2000;36:326-40.

896. Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA guidelines for ambulatory electrocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography). Developed in collaboration with the North American Society for Pacing and Electrophysiology. J Am Coll Cardiol 1999;34:912-48.

897. Hunt SM, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). 2001; American College of Cardiology Web site. Available at: http://www.acc.org/clinical/guidelines/failure/hf_index.htm. Accessed October 17, 2002.

898. Lauer MS, Okin PM, Larson MG, Evans JC, Levy D. Impaired heart rate response to graded exercise. Prognostic implications of chronotropic incompetence in the Framingham Heart Study. Circulation 1996;93:1520-6.

899. Lauer MS, Francis GS, Okin PM, Pashkow FJ, Snader CE, Marwick TH. Impaired chronotropic response to exercise stress testing as a predictor of mortality. JAMA 1999;281:524-9.

900. Cole CR, Blackstone EH, Pashkow FJ, Snader CE, Lauer MS. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med 1999;341:1351-7.

901. Cole CR, Foody JM, Blackstone EH, Lauer MS. Heart rate recovery after submaximal exercise testing as a predictor of mortality in a cardiovascularly healthy cohort. Ann Intern Med 2000;132:552-5.

902. Diaz LA, Brunken RC, Blackstone EH, Snader CE, Lauer MS. Independent contribution of myocardial perfusion defects to exercise capacity and heart rate recovery for prediction of all-cause mortality in patients with known or suspected coronary heart disease. J Am Coll Cardiol 2001;37:1558-64.

903. Watanabe J, Thamilarasan M, Blackstone EH, Thomas JD, Lauer MS. Heart rate recovery immediately after treadmill exercise and left ventricular systolic dysfunction as predictors of mortality: the case of stress echocardiography. Circulation 2001;104:1911-6.

904. Nishime EO, Cole CR, Blackstone EH, Pashkow FJ, Lauer MS. Heart rate recovery and treadmill exercise score as predictors of mortality in patients referred for exercise ECG. JAMA 2000;284:1392-8.

905. Shetler K, Marcus R, Froelicher VF, et al. Heart rate recovery: validation and methodologic issues. J Am Coll Cardiol 2001;38:1980-7.

906. McHam SA, Marwick TH, Pashkow FJ, Lauer MS. Delayed systolic blood pressure recovery after graded exercise: an independent correlate of angiographic coronary disease. J Am Coll Cardiol 1999;34:754-9.

907. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 Guideline Update for Exercise Testing. 2002. www.acc.org/clinical/guidelines/exercise/dirIndex.htm.

908. Marquis P, Fayol C, Joire JE, Leplege A. Psychometric properties of a specific quality of life questionnaire in angina pectoris patients. Qual Life Res 1995;4:540-6.

909. Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol 1995;25:333-41.

910. Wahrborg P, Emanuelsson H. The cardiac health profile: content, reliability and validity of a new disease-specific quality of life questionnaire. Coron Artery Dis 1996;7:823-9.

911. Alonso J, Permanyer-Miralda G, Cascant P, Brotons C, Prieto L, Soler-Soler J. Measuring functional status of chronic coronary patients. Reliability, validity and responsiveness to clinical change of the reduced version of the Duke Activity Status Index (DASI). Eur Heart J 1997;18:414-9.

912. Failde I, Ramos I. Validity and reliability of the SF-36 Health Survey Questionnaire in patients with coronary artery disease. J Clin Epidemiol 2000;53:359-65.

913. Dougherty CM, Dewhurst T, Nichol WP, Spertus J. Comparison of three quality of life instruments in stable angina pectoris: Seattle Angina Questionnaire, Short Form Health Survey (SF-36), and Quality of Life Index-Cardiac Version III. J Clin Epidemiol 1998;51:569-75.

914. Sullivan M, Genter F, Savvides M, Roberts M, Myers J, Froelicher V. The reproducibility of hemodynamic, electrocardiographic, and gas exchange data during treadmill exercise in patients with stable angina pectoris. Chest 1984;86:375-82.

915. Sanz ML, Mancini J, LeFree MT, et al. Variability of quantitative digital subtraction coronary angiography before and after percutaneous transluminal coronary angioplasty. Am J Cardiol 1987;60:55-60.

916. Davis RB, Iezzoni LI, Phillips RS, Reiley P, Coffman GA, Safran C. Predicting in-hospital mortality. The importance of functional status information. Med Care 1995;33:906-21.

917. Inouye SK, Peduzzi PN, Robison JT, Hughes JS, Horwitz RI, Concato J. Importance of functional measures in predicting mortality among older hospitalized patients. JAMA 1998;279:1187-93.

918. Reuben DB, Rubenstein LV, Hirsch SH, Hays RD. Value of functional status as a predictor of mortality: results of a prospective study. Am J Med 1992;93:663-9.

919. Scott WK, Macera CA, Cornman CB, Sharpe PA. Functional health status as a predictor of mortality in men and women over 65. J Clin Epidemiol 1997;50:291-6.

920. Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 1996.

921. Staquet MJ, Hays RDFPM, eds. Quality of Life Assessment in Clinical Trials: Methods and Practice. New York: Oxford University Press, 1998.

922. Sjoland H, Wiklund I, Caidahl K, Haglid M, Westberg S, Herlitz J. Improvement in quality of life and exercise capacity after coronary bypass surgery. Arch Intern Med 1996;156:265-71.

923. Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Fihn SD. Monitoring the quality of life in patients with coronary artery disease. Am J Cardiol 1994;74:1240-4.

924. Bliley AV, Ferrans CE. Quality of life after coronary angioplasty. Heart Lung 1993;22:193-9.

925. McHorney CA,Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36), II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-63.

926. McHorney CA,Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36), III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40-66.

927. Pollard WE, Bobbitt RA, Bergner M, Martin DP, Gilson BS. The Sickness Impact Profile: reliability of a health status measure. Med Care 1976;14:146-55.

928. Bergner M, Bobbitt RA, Pollard WE, Martin DP, Gilson BS. The sickness impact profile: validation of a health status measure. Med Care 1976;14:57-67.

929. Hunt SM, McEwen J, McKenna SP. Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract 1985;35:185-8.

930. Brown N, Melville M, Gray D,Young T, Skene AM, Hampton JR. Comparison of the SF-36 health survey questionnaire with the Nottingham Health Profile in long-term survivors of a myocardial infarction. J Public Health Med 2000;22:167-75.

931. Dempster M, Donnelly M. Measuring the health related quality of life of people with ischaemic heart disease. Heart 2000;83:641-4.

932. Visser MC, Fletcher AE, Parr G, Simpson A, Bulpitt CJ. A comparison of three quality of life instruments in subjects with angina pectoris: the Sickness Impact Profile, the Nottingham Health Profile, and the Quality of Well Being Scale. J Clin Epidemiol 1994;47:157-63.

933. Bliven BD, Green CP, Spertus JA. Review of available instruments and methods for assessing quality of life in anti-anginal trials. Drugs Aging 1998;13:311-320.

934. Gandjour A, Lauterbach KW. Review of quality-of-life evaluations in patients with angina pectoris. Pharmacoeconomics 1999;16:141-52.

935. Spertus J. Seattle Angina Questionnaire (SAQ). Available at: www.outcomes-trust.org/instruments.htm#saq. Accessed August 30, 2002.

936. Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002;105:788-93.

937. Laham RJ, Chronos NA, Pike M, et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. J Am Coll Cardiol 2000;36:2132-9.

938. Maxwell AJ, Zapien MP, Pearce GL, MacCallum G, Stone PH. Randomized trial of a medical food for the dietary management of chronic, stable angina. J Am Coll Cardiol 2002;39:37-45.

939. Rinfret S, Grines CL, Cosgrove RS, et al. Quality of life after balloon angioplasty or stenting for acute myocardial infarction. One year results from the Stent-PAMI trial. J Am Coll Cardiol 2001;38:1614-21.

940. Spertus JA, Jones PG, Coen M, et al. Transmyocardial CO(2) laser revascularization improves symptoms, function, and quality of life: 12-month results from a randomized controlled trial. Am J Med 2001;111:341-8.

941. Horvath KA, Aranki SF, Cohn LH, et al. Sustained angina relief 5 years after transmyocardial laser revascularization with a CO(2) laser. Circulation 2001;104:I81-4

942. Oesterle SN, Sanborn TA, Ali N, et al. Percutaneous transmyocardial laser revascularisation for severe angina: the PACIFIC randomised trial. Potential Class Improvement From Intramyocardial Channels. Lancet 2000;356:1705-10.

943. Seto TB, Taira DA, Berezin R, et al. Percutaneous coronary revascularization in elderly patients: impact on functional status and quality of life. Ann Intern Med 2000;132:955-8.

944. Fruitman DS,MacDougall CE, Ross DB. Cardiac surgery in octogenarians: can elderly patients benefit? Quality of life after cardiac surgery. Ann Thorac Surg 1999;68:2129-35.

945. Burkhoff D, Schmidt S, Schulman SP, et al. Transmyocardial laser revascularisation compared with continued medical therapy for treatment of refractory angina pectoris: a prospective randomized trial. ATLANTIC Investigators. Angina Treatments-Lasers and Normal Therapies in Comparison. Lancet 1999;354:885-90.

946. Weintraub WS, Culler SD, Kosinski A, et al. Economics, healthrelated quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina With Aggrastat [tirofiban]] and Determine Cost of Therapy with Invasive or Conservative Strategy)-TIMI 18 trial. Am J Cardiol 1999;83:317-22.

947. MacDonald P, Stadnyk K, Cossett J, Klassen G, Johnstone D, Rockwood K. Outcomes of coronary artery bypass surgery in elderly people. Can J Cardiol 1998;14:1215-22.

948. Spertus JA, Jones P, McDonell M, Fan V, Fihn SD. Health status predicts long-term outcome in outpatients with coronary disease. Circulation 2002;106:43-9.

949. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.

950. Lonn EM,Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-69.

951. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991;324:1098-104.

952. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.

953. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996;94:2756-67.

954. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;94:258-65.

955. Dell’Italia LJ, Oparil S. Bradykinin in the heart: friend or foe? Circulation 1999;100:2305-7.

956. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:1285-92.

957. Vaughan DE, Rouleau JL, Ridker PM, Arnold JM, Menapace FJ, Pfeffer MA. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation 1997;96:442-7.

957a.Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. [erratum appears in Lancet 2000;356:860] Lancet 2000;355:253-259.

958. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.

959. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-35.

960. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992;327:685-91.

961. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril onmortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.

962. van den Heuvel AF, Dunselman PH, Kingma T, et al. Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade. J Am Coll Cardiol 2001;37:470-4.

963. Rosano GM, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 1993;342:133-6.

964. Manhem K, Ahlm H, Dellborg M, Milsom I. Acute effects of transdermal estrogen in postmenopausal women with coronary artery disease. Using a clinically relevant estrogen dose and concurrent antianginal therapy. Cardiology 2000;94:86-90.

965. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Lowdose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation 2000;102:1906-11.

966. Deedwania PC, Carbajal EV, Nelson JR, Hait H. Anti-ischemic effects of atenolol versus nifedipine in patients with coronary artery disease and ambulatory silent ischemia. J Am Coll Cardiol 1991;17:963-9.

967. Pepine CJ, Cohn PF, Deedwania PC, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation 1994;90:762-8.

968. Chaitman BR, Stone PH, Knatterud GL, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study: impact of anti- ischemia therapy on 12-week rest electrocardiogram and exercise test outcomes. The ACIP Investigators. J Am Coll Cardiol 1995;26:585-93.

969. Davies RF, Habibi H, Klinke WP, et al. Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators. J Am Coll Cardiol 1995;25:619-25.

970. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.

971. Bedell SE, Jabbour S, Goldberg R, et al. Discrepancies in the use of medications: their extent and predictors in an outpatient practice. Arch Intern Med 2000;160:2129-34.

972. McDermott MM, Schmitt B, Wallner E. Impact of medication nonadherence on coronary heart disease outcomes. A critical review. Arch Intern Med 1997;157:1921-9.

973. Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA 1990;263:1653-7.

974. Horwitz RI, Viscoli CM, Berkman L, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet 1990;336:542-5.

975. Gallagher EJ, Viscoli CM, Horwitz RI. The relationship of treatment adherence to the risk of death after myocardial infarction in women. JAMA 1993;270:742-4.

976. Haynes RB, Montangue P, Olier T, McKibbon KA, Brouwers MC, Kanani R. Interventions for helping patients to follow prescriptions for medications. In: Cochran Database System. Oxford, UK: Update Software; 2000:CD000011.

977. Vega GL, Grundy SM. Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. Comparison of gemfibrozil vs lovastatin therapy. JAMA 1990;264:2759-63.

978. Abate N, Vega GL, Grundy SM. Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. Atherosclerosis 1993;104:159-71.

979. Sniderman AD. Apolipoprotein B and apolipoprotein AI as predictors of coronary artery disease. Can J Cardiol 1988;4(Suppl A):24A-30A.

980. Reinhart RA, Gani K, Arndt MR, Broste SK. Apolipoproteins AI and B as predictors of angiographically defined coronary artery disease. Arch Intern Med 1990;150:1629-33.

981. Sniderman A, Vu H, Cianflone K. Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels. Atherosclerosis 1991;89:109-16.

982. Tornvall P, Bavenholm P, Landou C, de Faire U, Hamsten A. Relation of plasma levels and composition of apolipoprotein Bcontaining lipoproteins to angiographically defined coronary artery disease in young patients with myocardial infarction. Circulation 1993;88:2180-9.

983. Westerveld HT, van Lennep JE, van Lennep HW, et al. Apolipoprotein B and coronary artery disease in women: a crosssectional study in women undergoing their first coronary angiography. Arterioscler Thromb Vasc Biol 1998;18:1101-7.

984. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996;94:273-8.

985. Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000; 101:477-84.

986. Lemieux I, Pascot A, Couillard C, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000;102:179-84.

987. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.

988. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8.

989. Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998;19(Suppl M):M8-14.

990. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81:7B-12B.

991. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults-The Evidence Report. National Institutes of Health. Obes Res 1998;6(Suppl 2):51S-209S.

992. Cheung MC, Zhao XQ, Chait A, Albers JJ, Brown BG. Antioxidant supplements block the response of HDL to simvastatinniacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol 2001;21:1320-6.

993. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:154-60.

994. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.

995. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:22-33.

996. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.

997. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-9.

998. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243-9.

999. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-33.

1000. Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001;104:499-503.

1001. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomized trial. Lancet 2001;358:951-7.

1002. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACPASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 1999;33:2092-197.

1003. Hautvast RW, DeJongste MJ, Staal MJ, van Gilst WH, Lie KI. Spinal cord stimulation in chronic intractable angina pectoris: a randomized, controlled efficacy study. Am Heart J 1998;136:1114-20.

1004. Jessurun GA, DeJongste MJ, Hautvast RW, et al. Clinical follow-up after cessation of chronic electrical neuromodulation in patients with severe coronary artery disease: a prospective randomized controlled study on putative involvement of sympathetic activity. Pacing Clin Electrophysiol 1999;22:1432-9.

1005. Norrsell H, Pilhall M, Eliasson T, Mannheimer C. Effects of spinal cord stimulation and coronary artery bypass grafting on myocardial ischemia and heart rate variability: further results from the ESBY study. Cardiology 2000;94:12-8.

1006. Jessurun GA, Ten Vaarwerk IA, DeJongste MJ, Tio RA, Staal MJ. Sequelae of spinal cord stimulation for refractory angina pectoris. Reliability and safety profile of long-term clinical application. Coron Artery Dis 1997;8:33-8.

1007. TenVaarwerk IA, Jessurun GA, DeJongste MJ, et al. Clinical outcome of patients treated with spinal cord stimulation for therapeutically refractory angina pectoris. The Working Group on Neurocardiology. Heart 1999;82:82-8.

1008. Murray S, Carson KG, Ewings PD, Collins PD, James MA. Spinal cord stimulation significantly decreases the need for acute hospital admission for chest pain in patients with refractory angina pectoris. Heart 1999;82:89-92.

1009. De Landsheere C, Mannheimer C, Habets A, et al. Effect of spinal cord stimulation on regional myocardial perfusion assessed by positron emission tomography. Am J Cardiol 1992;69:1143-9.

1010. Eliasson T, Albertsson P, Hardhammar P, Emanuelsson H, Augustinsson LE, Mannheimer C. Spinal cord stimulation in angina pectoris with normal coronary arteriograms. Coron Artery Dis 1993;4:819-27.

1011. de Jongste MJ, Nagelkerke D, Hooyschuur CM, et al. Stimulation characteristics, complications, and efficacy of spinal cord stimulation systems in patients with refractory angina: a prospective feasibility study. Pacing Clin Electrophysiol 1994;17:1751-60.

1012. Hautvast RW, Blanksma PK, DeJongste MJ, et al. Effect of spinal cord stimulation on myocardial blood flow assessed by positron emission tomography in patients with refractory angina pectoris. Am J Cardiol 1996;77:462-7.

1013. Greco S, Auriti A, Fiume D, et al. Spinal cord stimulation for the treatment of refractory angina pectoris: a two-year follow-up. Pacing Clin Electrophysiol 1999;22:26-32.

1014. Arora RR, Chou TM, Jain D, et al. The Multicenter Study of Enhanced External Counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol 1999;33:1833-40.

1015. Barsness G, Feldman AM, Holmes DR Jr, Holubkov R, Kelsey SF, Kennard ED. The International EECP Patient Registry (IEPR): design, methods, baseline characteristics, and acute results. Clin Cardiol 2001;24:435-42.

1016. Lawson WE, Hui JC, Lang G. Treatment benefit in the enhanced external counterpulsation consortium. Cardiology 2000;94:31-5.

1017. Aaberge L, Nordstrand K, Dragsund M, et al. Transmyocardial revascularization with CO2 laser in patients with refractory angina pectoris. Clinical results from the Norwegian randomized trial. J Am Coll Cardiol 2000;35:1170-7.

1018. Allen KB, Dowling RD, Fudge TL, et al. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. N Engl J Med 1999;341:1029-36.

1019. Frazier OH, March RJ, Horvath KA. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease. N Engl J Med 1999;341:1021-8.

1020. Held C, Hjemdahl P, Hakan WN, et al. Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris. Results from the APSIS study. The Angina Prognosis Study in Stockholm. Atherosclerosis 2000;148:179-88.

1021. Schofield PM, Sharples LD, Caine N, et al. Transmyocardial laser revascularisation in patients with refractory angina: a randomized controlled trial. Lancet 1999;353:519-24.

1022. Horvath KA, Smith WJ, Laurence RG, Schoen FJ, Appleyard RF, Cohn LH. Recovery and viability of an acute myocardial infarct after transmyocardial laser revascularization. J Am Coll Cardiol 1995;25:258-63.

1023. Yamamoto N, Kohmoto T, Gu A, DeRosa C, Smith CR, Burkhoff D. Angiogenesis is enhanced in ischemic canine myocardium by transmyocardial laser revascularization. J Am Coll Cardiol 1998;31:1426-33.

1024. Kwong KF, Kanellopoulos GK, Nickols JC, et al. Transmyocardial laser treatment denervates canine myocardium. J Thorac Cardiovasc Surg 1997;114:883-9.

1025. STS National Database. The Society of Thoracic Surgeons Web site. Available at: http://www.sts.org.

1026. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999;341:70-6.

1027. Bucher HC, Hengstler P, Schindler C, Guyatt GH. Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomized controlled trials. BMJ 2000;321:73-7.

1028. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 2000;35:1122-9.

1029. King SB III, Kosinski AS, Guyton RA, Lembo NJ, Weintraub WS. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). J Am Coll Cardiol 2000;35:1116-21.

1030. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronaryartery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117-24.

1031. Taylor HA, Deumite NJ, Chaitman BR, Davis KB, Killip T, Rogers WJ. Asymptomatic left main coronary artery disease in the Coronary Artery Surgery Study (CASS) registry. Circulation 1989;79:1171-9.

1032. Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 2001;37:2215-38.

1033. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA guidelines for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999;34:1262-347.

1034. Campeau L. Grading of angina pectoris [letter]. Circulation 1976;54:522-3.

1035. Wiklund I, Comerford MB, Dimenas E. The relationship between exercise tolerance and quality of life in angina pectoris. Clin Cardiol 1991;14:204-8.

1036. Marquis P, Fayol C, Joire JE. Clinical validation of a quality of life questionnaire in angina pectoris patients. Eur Heart J 1995;16:1554-60.

1037. Goldman L, Hashimoto B, Cook EF, Loscalzo A. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation 1981;64:1227-34.

1038. Hlatky MA, Boineau RE, Higginbotham MB, et al. A brief selfadministered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol 1989;64:651-4.

1039. Hillers TK, Guyatt GH, Oldridge N, et al. Quality of life after myocardial infarction. J Clin Epidemiol 1994;47:1287-96.

1040. Valenti L, Lim L, Heller RF, Knapp J. An improved questionnaire for assessing quality of life after acute myocardial infarction. Qual Life Res 1996;5:151-61.

1041. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Longterm stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577-81.

1042. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.

1043. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996;156:286-9.

1044. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998;351:28-31.

1045. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with noninsulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.

1046. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.

1047. Zuanetti G, Latini R, Maggioni AP, Franzosi M, Santoro L, Tognoni G. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 1997;96:4239-45.

1048. Shindler DM, Kostis JB,Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996;77:1017-20.

1049. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999;353:611-6.

1050. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.

1051. Allen KB, Dowling RD, DelRossi AJ, et al. Transmyocardial laser revascularization combined with coronary artery bypass grafting: a multicenter, blinded, prospective, randomized, controlled trial. J Thorac Cardiovasc Surg 2000;119:540-9.

1052. Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001;104:1577-9.

Copyright © 2003 by the American College of Cardiology and American Heart Association, Inc.